

# Research in Your Backyard

Developing Cures, Creating Jobs



**PHARMACEUTICAL  
CLINICAL TRIALS IN  
NEW YORK**

Dots show locations of clinical trials in the state.

**PhRMA**

# Executive Summary

## Clinical Trials in New York State

- Biopharmaceutical research companies are conducting or have conducted more than 6,200 clinical trials of new medicines in collaboration with the state's clinical research centers, university medical schools and hospitals (1999 to present).
- Of the 6,282 clinical trials, 3,255 target or have targeted the nation's six most debilitating chronic diseases—**asthma, cancer, diabetes, heart disease, mental illnesses and stroke.**
- These 6,282 New York-based clinical trials represent approximately one-third of all clinical trials in the United States.

*“For many patients with chronic health problems and other serious medical conditions, the opportunity to participate in clinical trials for new treatments offers great hope, promise, and piece of mind. With thousands of clinical trials being conducted all over New York State, patients have access to additional therapeutic options that would not otherwise be available to them. These additional therapeutic options provide an alternative for patients where other treatments have failed. Clinical trials help save patients’ lives and paves the way for cures—leading our communities to a better, healthier future.”*

—Geri Barish, President,  
1 in 9: The Long Island Breast Cancer Action Coalition

*“The biotechnology industry, including biopharmaceutical research and the development of new medicines, is an important and growing part of New York State’s economy. Biopharmaceutical research firms frequently work in partnership with hospitals, medical schools and other research institutions, which facilitates the participation of New Yorkers in thousands of clinical trials throughout the state. Biopharmaceutical research is also a boon to local economies in New York, supporting an estimated 201,000 jobs and generating millions in tax revenues.”*

—Nathan Tinker, Executive Director,  
New York Biotechnology Association

## Economic Benefits of Clinical Trials in New York State

- Biopharmaceutical research companies have been an important source of jobs, tax revenue and research spending in New York.
- A study by Archstone Consulting found that in 2008 the industry supported more than 201,000 jobs throughout the state.
- Employees working directly for the companies were paid \$2.8 billion, leading to more than \$99 million

in state taxes and more than \$646 million in federal taxation.

- Biopharmaceutical research firms that year also invested \$2.1 billion in research and development and supported \$50.9 billion in products and services.
- Company employees in New York include life sciences researchers, management executives, office and administrative support workers, engineers, architects, computer and math experts and sales representatives.

## About Clinical Trials

- In the development of new medicines, clinical trials are conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug Administration (FDA) to approve treatments.
- Clinical tests of new drugs are conducted in three phases and account for an average of seven of the 10 to 15 years it takes to take a new drug from development to patients.
- Clinical trials for a given drug or treatment involve thousands of volunteer patient participants, and the generation of tens of thousands of pages of technical and scientific data.

- Clinical trials are responsible for 45 to 75 percent of the \$1.2 billion average cost of developing one new cutting-edge biotechnology medicine.
- Biopharmaceutical companies frequently hire local research institutions to conduct the tests.
- For patients, the trials offer another potential therapeutic option. Clinical tests may provide a new avenue of care for some chronic disease sufferers who are still searching for the medicines that are best for them.
- All clinical trials must be reviewed and approved by an Institutional Review Board (IRB), an independent committee of physicians, statisticians, local community advocates and others to ensure a trial is ethically conducted and patient rights are protected.
- Clinical trial progress reports must be submitted at least annually to the FDA and the IRB.
- All facilities that conduct or support biomedical research involving patients must comply with federal regulations and have an IRB.

## Clinical Trials and Chronic Diseases

- Chronic diseases pose the greatest threats to our nation's health and our ability to treat and prevent medical conditions.
- According to the Centers for Disease Control and Prevention, today, in the United States:
  - Patients with chronic diseases **account for 75 cents of every dollar** spent on health care.
  - Chronic diseases are the **leading cause of death and disability**.
  - Chronic diseases are a **leading driver of rising health care costs** with expenses totaling billions of dollars every year.

### Clinical Trials in New York since 1999— Completed and Active

All Clinical Trials	Six Major Chronic Diseases
6,282	3,255

Source: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Note: Search criteria = New York, Phase I, II, III; industry only.

Search performed 4/17/2012.

Clinical Trials in New York Communities						
Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Albany	1	22	11	7	6	3
Amherst	—	2	—	1	4	—
Binghamton	—	1	2	1	—	1
Bronx	2	51	4	12	8	3
Brooklyn	3	8	7	7	25	1
Buffalo	—	59	9	10	9	5
Commack	—	17	—	—	2	—
Fresh Meadows	—	6	—	—	11	—
Great Neck	2	9	1	—	1	—
Kingston	—	2	1	3	2	1
Lake Success	1	45	—	—	—	—
Manhasset	—	7	—	2	3	—
Mineola	2	4	6	3	—	2
New Hyde Park	1	21	5	1	—	—
New York City	5	331	23	34	64	9
Poughkeepsie	—	9	—	4	—	2
Rochester	5	42	7	11	38	5
Staten Island	—	10	1	1	2	—
Syracuse	4	32	4	5	2	1
Troy	—	10	1	3	—	—
Utica	2	7	—	3	—	—
West Seneca	—	—	6	2	3	2
White Plains	—	7	1	1	1	1
Williamsville	—	1	1	6	—	2

Source: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Note: Search criteria = New York, Phase I, II; industry only. Search performed 4/17/2012. See Appendix for detailed information about these clinical trials. Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city.

## Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	67	12
Cancer	1,917	481
Diabetes	355	46
Heart Disease	242	50
Mental Illness	623	111
Stroke	51	16
<b>Total</b>	<b>3,255</b>	<b>716</b>

Source: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Note: Search criteria = New York, Phase I, II, III; industry only. Search performed 4/17/2012. Some clinical trials appear in more than one disease category.

- Biopharmaceutical research companies are developing new medicines to help treat those conditions that are taking an unprecedented toll on American lives, and many of these medicines are being tested today in clinical trials throughout New York.
- Since 1999, biopharmaceutical research companies are sponsoring or have sponsored 3,255 clinical trials of potential new medicines in New York state alone for **asthma, cancer, heart disease, stroke, diabetes and mental illnesses**. Of these trials, 716 are either not yet recruiting or are just now seeking New York patients.
- Many of the state's clinical tests involve collaborations with such respected local institutions as **Mount Sinai School of Medicine, Beth Israel Hospital, New York University Medical Center, and Columbia University Medical Center** in New York City, the

University of Rochester–Strong Memorial Hospital in Rochester, the Joslin Diabetes Center in Syracuse, and the University of Buffalo in Buffalo.

- Many of the medicines being clinically tested here are new-generation biotechnology treatments.

*“These are challenging economic times. Our growing biotechnology and biopharmaceutical sector is a critical part of New York’s past, present and future. We need to ensure that the research that takes place across the state in hospitals, medical schools and other institutions is fully supported. This research is what sets us apart from other regions in the country and it generates huge numbers of jobs and investment into New York.”*

—Mike Oates, President and CEO,  
Hudson Valley Economic Development Corporation;  
NY BioHud Valley

# Clinical Trials in New York

Clinical tests of new medicines are a vitally important part of the drug development and approval process—they account for 45 to 75 percent of the \$1.2 billion average cost of developing a new drug and are conducted to determine the safety and effectiveness of that treatment in patients.

Some trials are also conducted to compare existing treatments and some are done to learn if a drug is appropriate for a different patient population, such as children. Still others are conducted to find ways to make existing approved drugs more effective and easier to use with fewer side effects.

It's essential that trials be conducted properly so that clinicians and drug reviewers can develop accurate assessments of the efficacy and safety of medicines used by patients. The FDA is a vigilant regulatory agency and its pharmaceutical review officers are effective in detecting flawed information.

Questionable or confusing data can lead to lengthy delays in product approval or outright FDA rejection of a new drug.

Biopharmaceutical research companies are looking for the best physicians and research institutions to meticulously help design and conduct their clinical trials to determine whether a medicine is safe and effective. Side effects must be painstakingly documented and a determination made as to whether they occur too often and are dangerous.

Clinical tests involve three phases and thousands of volunteer patients and are often conducted at multiple sites

## Clinical Trials for Top Chronic Diseases

Chronic Disease	All Clinical Trials	Clinical Trials Still Recruiting
Asthma	67	12
Cancer	1,917	481
Diabetes	355	46
Heart Disease	242	50
Mental Illness	623	111
Stroke	51	16
<b>Total</b>	<b>3,255</b>	<b>716</b>

Source: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Note: Search criteria = New York, Phase I, II, III; industry only. Search performed 4/17/2012. Some clinical trials appear in more than one disease category.

around the country. In New York, biopharmaceutical companies have the opportunity of conducting trials at the states' well-respected university medical schools, comprehensive cancer centers and clinical trial research centers. According to *U.S. News and World Report*, **Columbia University** ranked 10th, **Cornell University's Weill Medical College** ranked 17th, **Mount Sinai School of Medicine** ranked 18th, **New York University** ranked 30th, the **University of Rochester** ranked 32nd, **Albert Einstein College of Medicine at Yeshiva University** ranked 41st, the **SUNY University at Buffalo** ranked 55th, **Stony Brook University-SUNY** ranked 56th, and **SUNY Upstate Medical University at Syracuse** ranked 82nd among last year's top 100 research-oriented medical schools in the United States.



**Asthma** is a debilitating condition for more than 24 million Americans, including 7 million children under the age of 18. The toll is also severe in New York—in 2008, an estimated 1.3 million adults and 475,000 children suffered from asthma, according to the New York State Department of Health.

Currently, 12 clinical trials of new asthma medicines are recruiting patients in New York. Trials are being conducted at the **Bronx Medical Center for Pulmonary, Asthma and Sleep Disorders**, the **Maimonides Medical Center** in Brooklyn, the **St. Elizabeth Health Center** in Utica, and the **AAIR Research Center** in Rochester.

**Cancer**, the second leading cause of death in the United States, now afflicts nearly 12 million Americans, according to the National Cancer Institute. In New York, more than 109,000 new cancer cases will be diagnosed this year and 34,140 victims in the state will die, according to the American Cancer Society.

Currently, 481 clinical trials of new cancer medicines are recruiting patients in New York. In New York City, biopharmaceutical companies are collaborating on the tests with such prominent institutions as the **Memorial Sloan-Kettering Cancer Center**, the **New York University Cancer Institute**, the **Beth Israel Cancer Center**, and the **Weill Cornell Cancer Center**. Other trials are being conducted at the **Albany Cancer Center** in Albany, the **Roswell Park Cancer Institute** in Buffalo, **North Shore University Hospital** in Manhasset, the **Guthrie Cancer Center** in Corning, and the **James P. Wilmont Cancer Center** in Rochester.

**Diabetes** affects more than 25 million Americans—about 8 percent of the U.S. population—and nearly one-third are unaware they have the disease. In New York, about 8.5 percent of adults have been diagnosed with diabetes, according to the New York State Department of Health.

Currently, 46 diabetes clinical tests are seeking patients in New York. The trials are being conducted at the **Women and Children's Hospital of Buffalo**, the **Digiovanna Institute for Medical Education and Research** in North Massapequa, the **Jacobi Medical Center** in the Bronx, the **Rogosin Institute**, the **Mount Sinai School of Medicine**, the **Columbia University Medical Center** and **St. Luke's-Roosevelt Hospital Center** in New York City.

**Heart disease and stroke** are the first and fourth leading disease causes of death in the United States and in New York. According to the American Heart Association, more than 82 million Americans are affected by these diseases. In New York, in 2009, more than 46,000 residents died from some form of heart disease and more than 5,800 died from a stroke, according to the New York State Department of Health.

Currently, 50 heart disease and 16 stroke clinical tests are seeking patients in New York. In New York City, trials are being conducted at **New York Presbyterian Hospital**, the **St. Luke's-Roosevelt Hospital Center**, **New York University Langone Medical Center**, **Mount Sinai Medical Center** and **Lennox Hill Hospital**. Other trials are being conducted at the **University of Buffalo**, the **Hudson Valley Heart Center** in Poughkeepsie, the **University of Rochester-Strong Memorial Hospital**, the **Albany Medical Center**, and **St. Francis Hospital** in Roslyn.

**Mental illness** affects nearly 60 million Americans suffering from some form of the disease—from anxiety to depression to schizophrenia to eating disorders. In New York, nearly 673,000 adults live with serious mental illness and about 204,000 children live with serious mental health conditions, according to the National Alliance on Mental Illness.

Currently, 111 clinical trials for mental illness are recruiting patients in New York. In New York City, trials are taking place at the **Weill Cornell Medical Center**, the **New York State Psychiatric Institute at Columbia University**, and the **Severe Autism Center at Mount Sinai Medical Center**. Other trials are being conducted at **Finger Lakes Clinical Research** in Rochester, **North Shore Hospital** in Manhasset, the **Zucker Hillside Hospital** in Glen Oaks, **SUNY Upstate Medical University** in Syracuse, and the **Behavioral Institute at Hofstra University** in Great Neck.

*Physicians and patients can find out about clinical trials being conducted across the state in collaboration with local institutions by accessing [www.clinicaltrials.gov](http://www.clinicaltrials.gov), a database sponsored by the National Institutes of Health. Information on medicines in development is also available on [www.phrma.org](http://www.phrma.org), the website of the Pharmaceutical Research and Manufacturers of America (PhRMA).*

# What is the Clinical Trial Experience?

Clinical trials are research studies which grant participants early access to new drugs, treatments, and therapies that are being developed to help combat chronic, serious and life threatening diseases. By volunteering for a clinical trial, patients take an active role in their healthcare by helping researchers test new medical treatments, and helping to find better ways of using existing treatments so they will be more effective, easier to use, and result in fewer or more tolerable side effects. In New York alone, thousands of clinical trials are taking place to study diseases like asthma, cancer, diabetes, heart disease, mental illness, and stroke.

## Phases of Clinical Trials

There are three phases of testing used to evaluate new drugs and treatments:

**Phase I**—This phase is designed to test the safety of a new drug or treatment. Researchers test the drug on a small group of people (20–80) and evaluate safety aspects of the drug, such as safe dosage range, the best way of administering the treatment (pill form vs. a shot for example), and identifying what, if any, side effects present themselves.

**Phase II**—This phase is designed to test efficacy and to further measure safety. The treatment is given to a larger group of people (100–300) to make sure the treatment

works correctly, and to try to identify any less-common side effects, which may appear when more people are tested. This phase is usually placebo-controlled and double-blinded, meaning neither the patient nor the doctor knows whether the patient is getting the placebo or the real treatment.

**Phase III**—This phase is meant to confirm efficacy and safety information, monitor known side effects, and compare the experimental treatment to commonly used ones to see which work better. A large group (1000–3000) receives this treatment, and like Phase II, it is usually placebo-controlled and double-blinded.

## Learning About and Accessing Clinical Trials

There are several ways patients can access information about clinical trials. Healthcare providers are aware of clinical trials being conducted at hospitals, universities, and other leading healthcare facilities, and can be valuable sources of information for patients looking to participate. Patients can also turn to hospitals' and universities' websites to see what studies are being conducted in their area, and what the eligibility criteria are for each trial. Some hospitals, like The Memorial Sloan-Kettering Center, use their website to list several clinical trials taking place in New York, and offer programs where participants can reach out to other patients who have been involved



in clinical trials. More information about clinical trials and volunteering can be found at <http://centerwatch.com/>, a PhRMA-recommended website.

## What to Expect

Treatments for clinical trials usually take place in a doctor's office. Patients may need to devote more time to doctor's visits and physical exams than they would normally. They may also have additional responsibilities, like keeping a daily log of their health. All prospective participants must sign an informed consent document saying they understand the clinical trial is research, and that they can leave the trial at any time. Once they have consulted with their healthcare providers, patients can reach out via phone or email to express interest in participating, at which point a pre-screening interview will take place. If the patient matches the trial's criteria, they will then be able to enroll in the study.

## Patient Expenses

Patients should always ask during their pre-screening interviews what it will cost them to participate in a clinical trial. Sponsors for clinical trials will usually pay for all research-related costs and any additional testing or doctor's visits the trial requires. Patients or their insurance companies may be asked to pay for any routine treatments that they would normally undergo for their

disease. However, some health plans do not pay for these costs once a patient joins the trial. Patients should be sure to check with the clinic conducting the trial to find out if they or their insurance companies will be charged with any fees, and should make sure their insurance companies will cover the costs of routine exams if they join a trial.

Non-local patients should be sure to look into the sponsoring clinic's policy on patient living arrangements. The National Cancer Institute, for example, makes patients responsible for their own travel costs for the initial screening visits. Once a patient is enrolled, the Institute will pay for transportation costs for all subsequent trial-related visits. These patients will receive a small per diem for food and lodging. The policy will differ from clinic to clinic.

# New Generation Medicines in Development

Many of the medicines being tested in New York are cutting-edge biotechnology drugs.

America's biopharmaceutical research companies are using biotechnology to develop hundreds of medicines and vaccines today. And New York is one of the states where extensive new-generation research and development work is being done.

Through biotechnology, new ways are being developed to not only more effectively treat disease, but also to predict, preempt and prevent it.

Biotechnology medicines are developed through biological processes using living cells or organisms, rather than traditional chemical synthesis, the mainstay of pharmaceutical development for decades.

Such novel treatments use a variety of new approaches to treat disease. For example, a monoclonal antibody is a laboratory-made version of the naturally occurring immune system protein that binds to and neutralizes foreign invaders. Interferons are proteins that interfere with the ability of a cell to reproduce.

Antisense drugs, meanwhile, are medicines that interfere with the communication process that tells a cell to produce an unwanted protein. In addition, nanotechnology is being used in biotechnology research to provide drug-delivery systems, new treatments and diagnostics.

Many of the medicines in clinical testing at New York medical schools and research centers feature these technologies. For example:

- A genetically-modified virus-based vaccine to treat melanoma.
- A monoclonal antibody for the treatment of cancer.
- An antisense medicine for the treatment of cancer.
- A recombinant fusion protein to treat age-related macular degeneration and diabetic macular edema.
- A monoclonal antibody in the pipeline targets lupus and various types of cancer.
- A therapeutic vaccine, designed to jump-start the immune system to fight disease, is in development for lung cancer and melanoma.

These are only a portion of the examples of new ways the nation's biopharmaceutical companies and New York research institutions are working together to attack disease. The biotechnology medicines and vaccines in development promise to push the frontiers of science and potentially bring more and better treatments to patients.

# Conclusion

Biopharmaceutical companies' close collaboration with clinicians and research institutions in New York benefits patients, the state's economy and the advancement of science and patient care. Clinical trial work is good business for the state's medical schools and clinical research centers and the medicines being tested are often cutting-edge cell and protein treatments with the potential to be safer and more effective than older chemical compound drugs.

What's more, New Yorkers contemplating participation in clinical trials in consultation with their doctors, have a wide range of choices—more than 700 tests of new medicines for the six most debilitating chronic diseases in America are underway in communities large and small all over the state and they need patient volunteers.

## The Drug Discovery, Development and Approval Process

It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000 compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Clinical Trials							
Discovery/ Preclinical Testing		Phase I	Phase II	Phase III	FDA	Phase IV	
Years	6.5	1.5	2	3.5	1.5		
Test Population	Laboratory and animal studies	20 to 100 healthy volunteers	100 to 500 patient volunteers	1,000 to 5,000 patient volunteers	Review process/ approval	Additional post-marketing testing required by FDA	
Purpose	Assess safety, biological activity and formulations	Determine safety and dosage	Evaluate effectiveness, look for side effects	Confirm effectiveness, monitor adverse reactions from long-term use			
Success Rate	5,000 compounds evaluated		5 enter trials		1 approved		

File IND at FDA

File NDA/BLA at FDA

## The Drug Development and Approval Process

**The U.S. system of new drug approvals is perhaps the most rigorous in the world.**

It takes 10-15 years, on average, for an experimental drug to travel from lab to U.S. patients, according to the Tufts Center for the Study of Drug Development, based on drugs approved from 1994 through 1998. Only five in 5,000 compounds that enter preclinical testing make it to human testing. And only one of those five is approved for sale.

On average, it costs a company \$1.2 billion, including the cost of failures, to get one new medicine from the laboratory to U.S. patients, according to a 2007 study by the Tufts Center for the Study of Drug Development.

Once a new compound has been identified in the laboratory, medicines are developed as follows:

**Preclinical Testing.** A pharmaceutical company conducts laboratory and animal studies to show biological activity of the compound against the targeted disease, and the compound is evaluated for safety.

**Investigational New Drug Application (IND).** After completing preclinical testing, a company files an IND with the U.S. Food and Drug

Administration (FDA) to begin to test the drug in people. The IND shows results of previous experiments; how, where and by whom the new studies will be conducted; the chemical structure of the compound; how it is thought to work in the body; any toxic effects found in the animal studies; and how the compound is manufactured. All clinical trials must be reviewed and approved by the Institutional Review Board (IRB) where the trials will be conducted. Progress reports on clinical trials must be submitted at least annually to FDA and the IRB.

**Clinical Trials, Phase I.** These tests usually involve about 20 to 100 normal, healthy volunteers. The tests study a drug's safety profile, including the safe dosage range. The studies also determine how a drug is absorbed, distributed, metabolized, and excreted as well as the duration of its action.

**Clinical Trials, Phase II.** In this phase, controlled trials of approximately 100 to 500 volunteer patients (people with the disease) assess a drug's effectiveness and determine the early side effect profile.

**Clinical Trials, Phase III.** This phase usually involves 1,000 to 5,000 patients in clinics and

hospitals. Physicians monitor patients closely to confirm efficacy and identify adverse events.

**New Drug Application (NDA)/Biologic License Application (BLA).** Following the completion of all three phases of clinical trials, a company analyzes all of the data and files an NDA or BLA with FDA if the data successfully demonstrate both safety and effectiveness. The applications contain all of the scientific information that the company has gathered. Applications typically run 100,000 pages or more. The average review time for the 21 new therapeutics approved by the FDA in 2010 was 14.8 months.

**Approval.** Once FDA approves an NDA or BLA, the new medicine becomes available for physicians to prescribe. A company must continue to submit periodic reports to FDA, including any cases of adverse reactions and appropriate quality-control records. For some medicines, FDA requires additional trials (Phase IV) to evaluate long-term effects.

Discovering and developing safe and effective new medicines is a long, difficult, and expensive process. PhRMA member companies invested an estimated \$49.5 billion in research and development in 2011.

# The Good News – Many Clinical Trials are Still Recruiting

There are 716 clinical trials recruiting in New York. These trials target the top six chronic diseases and other debilitating diseases affecting Americans and New Yorkers.

Clinical Trials in New York Communities						
Location	Asthma	Cancer	Diabetes	Heart Disease	Mental Illness	Stroke
Albany	1	22	11	7	6	3
Amherst	—	2	—	1	4	—
Binghamton	—	1	2	1	—	1
Bronx	2	51	4	12	8	3
Brooklyn	3	8	7	7	25	1
Buffalo	—	59	9	10	9	5
Commack	—	17	—	—	2	—
Fresh Meadows	—	6	—	—	11	—
Great Neck	2	9	1	—	1	—
Kingston	—	2	1	3	2	1
Lake Success	1	45	—	—	—	—
Manhasset	—	7	—	2	3	—
Mineola	2	4	6	3	—	2
New Hyde Park	1	21	5	1	—	—
New York City	5	331	23	34	64	9
Poughkeepsie	—	9	—	4	—	2
Rochester	5	42	7	11	38	5
Staten Island	—	10	1	1	2	—
Syracuse	4	32	4	5	2	1
Troy	—	10	1	3	—	—
Utica	2	7	—	3	—	—
West Seneca	—	—	6	2	3	2
White Plains	—	7	1	1	1	1
Williamsville	—	1	1	6	—	2

Source: [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Note: Search criteria = New York, Phase I, II; industry only. Search performed 4/17/2012. See Appendix for detailed information about these clinical trials. Disease columns will not match totals in the Appendix because some clinical trials are recruiting in more than one city.

# The Good News—Many Clinical Trials are Still Recruiting

(continued)

## Asthma—Leading Institutions Conducting Clinical Trials

AAIR Research Center, Rochester  
Bronx Medical Center for Pulmonary, Asthma and  
Sleep Disorders, Bronx  
Maimondes Medical Center, Brooklyn  
MedHex Health, New York City  
St. Elizabeth Health Center, Utica

## Cancer—Leading Institutions Conducting Clinical Trials

Accumed Research Associates, Garden City  
Advanced Oncology Associates, Armonk  
Albany Cancer Center at Patroon Creek, Albany  
Albany Medical Center, Albany  
Albert Einstein College of Medicine at Yeshiva  
University, Bronx  
Arena Oncology Associates, New Hyde Park  
Arthur Smith Institute for Urology, New Hyde Park  
Bellevue Hospital Center, New York City  
Benedictine Hospital, Kingston  
Beth Israel Comprehensive Cancer Center,  
New York City  
Brain and Spine Surgeons of New York and Northern  
Westchester Hospitals, White Plains  
Bronx Lebanon Hospital, Bronx  
Brooklyn Urology Research Group, Brooklyn  
Capital Region Medical Research Foundation, Albany  
Children's Hospital at New York Presbyterian,  
New York City  
Clinical Research Alliance, Lake Success  
Columbia University Medical Center, New York City  
Community Care Physicians, Albany  
Dent Neurosciences Research Institute, Amherst  
Eastchester Center for Cancer Care, Bronx  
Elizabeth Wende Breast Care, Rochester  
Goshen Medical Associates, Goshen  
Guthrie Cancer Center, Corning  
Herbert Irving Comprehensive Cancer Center of  
Columbia University, New York City

Huntington Hospital, Huntington  
Interlakes Foundation, Rochester  
James P. Wilmont Cancer Center at the University  
of Rochester, Rochester  
Long Island Brain Tumor Centre at Neurological  
Surgery, Commack and Great Neck  
Long Island Jewish Medical Center, New Hyde Park  
Long Island Skin Cancer and Dermatologic Surgery,  
Smithtown  
Male and Female Urology, Staten Island  
Memorial Sloan-Kettering Cancer Center at Suffolk,  
Commack  
Memorial Sloan-Kettering Cancer Center, New York  
City  
Mercy Medical Center (Memorial Sloan-Kettering  
Cancer Center), Rockville Centre  
Montefiore Medical Center, Bronx  
Monter Cancer Center, New Hyde Park  
Mount Sinai School of Medicine, New York City  
New York Downtown Hospital, New York City  
New York Medical College, Valhalla, Hawthorne  
New York Methodist Hospital, Brooklyn  
New York Oncology Hematology, Albany, Amsterdam,  
Latham, Troy  
New York Presbyterian Hospital, New York City  
New York University Cancer Institute, New York City  
North Shore Hematology/Oncology Associates, East  
Setauket  
North Shore University Hospital, Manhasset  
Phelps Memorial Hospital Center (Memorial  
Sloan-Kettering Cancer Center), Sleepy Hollow  
Premier Medical Group of the Hudson Valley,  
Poughkeepsie  
Queens Cancer Center of Queens Hospital Center,  
Jamaica  
Queens Medical Associates, Fresh Meadows  
Research Foundation of State University of New York,  
Syracuse  
Richmond University Medical Center, Staten Island  
Roswell Park Cancer Institute, Buffalo

Ruttenberg Cancer Clinic at Mount Sinai Medical Center, New York City  
Schwartz Gynecologic Oncology, Brightwaters  
Sciode Medical Associates, Bronx  
South Nassau Community Hospital, Oceanside  
St. Luke's-Roosevelt Hospital Center, New York City  
Staten Island Urological Research, Staten Island  
Steven D. Hassenfeld Children's Center at NYU, New York City  
Stony Brook Cancer Center, Stony Brook  
SUNY Downstate Medical Center, Brooklyn  
SUNY Upstate Medical University, Syracuse  
Syracuse Veteran's Affairs Medical Center, Syracuse  
Tisch Cancer Institute at Mount Sinai Medical Center, New York City  
Urological Institute of Northeastern New York, Albany  
VA Western New York Healthcare System, Buffalo  
Weill Cornell Medical College, New York City  
Winthrop University Hospital, Mineola

### **Diabetes—Leading Institutions Conducting Clinical Trials**

Albany Medical Center, Albany  
Albany Medical College, Albany  
Burke Medical Research Institute, White Plains  
Central New York Clinical Research, Manlius  
Clinical Research Development Associates, Rosedale  
Columbia University Medical Center, New York City  
Digiovanna Institute for Medical Education & Research, North Massapequa  
Helen L. & Martin S. Kimmel Wound Healing Center at the NYU Hospital for Joint Diseases, New York City  
Hypertension and Renal Research Group, Orchard Park  
Jacobi Medical Center, Bronx  
Joslin Diabetes Center, Syracuse  
Medex Healthcare Research, New York City  
MedHex Health, New York City  
Millard Fillmore Gates Hospital, Buffalo  
Mount Sinai School of Medicine, New York City  
Nephrology & Hypertension Associates, Bronx  
Nephrology Associates, Flushing  
New York Harbor Healthcare, New York City

New York Methodist Hospital, Brooklyn  
North Shore Diabetes and Endocrine Associates, New Hyde Park  
Southgate Medical Group, West Seneca  
Southtowns Neurology of Western New York, West Seneca  
St. Luke's-Roosevelt Hospital Center, New York City  
SUNY Buffalo, Buffalo  
SUNY Downstate, Brooklyn  
The Medical Research Network, New York City  
The Rogosin Institute, New York City  
University of Rochester, Rochester  
Women and Children's Hospital of Buffalo, Buffalo

### **Heart Disease and Stroke—Leading Institutions Conducting Clinical Trials**

Albany Associates in Cardiology, Albany  
Buffalo Cardiology & Pulmonary Associates, Buffalo, Williamsville  
Buffalo Heart Group-Mercy Hospital, Buffalo  
Buffalo Heart Group-Millard Fillmore Gates Circle Hospital, Buffalo  
Burke Medical Research Institute, White Plains  
Central New York Cardiology, Utica  
Columbia University Medical Center, New York City  
Hudson Valley Heart Center, Poughkeepsie  
Huntington Hospital, Huntington  
Lenox Hill Hospital, New York City  
Long Island Jewish Hospital, New Hyde Park  
Montefiore Medical Center, Bronx  
Mount Sinai Medical Center, New York City  
New York Methodist Hospital, Brooklyn  
New York Presbyterian Hospital, New York City  
New York University Langone Medical Center, New York City  
North Shore University Hospital, Manhasset  
Southtowns Neurology of Western New York, West Seneca  
St. Francis Hospital, Roslyn  
St. Luke's-Roosevelt Hospital Center, New York City  
Stony Brook University Medical Center, Stony Brook  
SUNY Buffalo, Buffalo  
SUNY Downstate, Brooklyn



# The Good News—Many Clinical Trials are Still Recruiting

(continued)

University Cardiovascular Associates, Rochester  
University of Buffalo, Buffalo  
University of Rochester-Strong Memorial Hospital,  
Rochester

## Mental Illness—Leading Institutions Conducting Clinical Trials

Albert Einstein College of Medicine-Division of  
Substance Abuse, New York City  
Anxiety and Depression Clinic at Montefiore Medical  
Center, Bronx  
Behavioral Institute at Hofstra University, Great Neck  
Behavioral Medical Research of Brooklyn, Brooklyn  
Behavioral Medical Research of Staten Island, Staten  
Island  
Bellevue Hospital Center, New York City  
Bioscience Research, Mount Kisco  
Brooklyn Medical Institute, Brooklyn  
Clinlabs, New York City  
Columbia University, New York City  
Comprehensive Clinical Development, Fresh Meadows  
Eastside Comprehensive Medical Center, New York City  
Fieve Clinical Services, New York City  
Finger Lakes Clinical Research, Rochester  
James J. Peters VA Medical Center, Bronx  
Medical and Behavioral Health Research, New York  
City  
Mount Sinai School of Medicine, New York City  
Neurobehavioral Research, Cedarhurst  
Neuropharmacology Services, New York City  
New York Eye and Ear Infirmary, New York City  
New York State Institute for Basic Research in  
Developmental Disabilities, Staten Island  
New York State Psychiatric Institute at Columbia  
University, New York City  
North Shore Hospital, Manhasset  
Research Foundation for Mental Hygiene, New York  
City

Richmond Behavioral Associates, Staten Island  
Seaver Autism Center at Mount Sinai Medical Center,  
New York City  
Social Psychiatric Research Institute, Brooklyn  
Stony Brook University Medical Center, Stony Brook  
Substance Abuse Treatment and Research Service, New  
York City  
SUNY Buffalo Jacobs Neurological Institute, Buffalo  
SUNY Upstate Medical University, Syracuse  
Synergy First, Brooklyn  
University of New York, Buffalo  
University of Rochester, Rochester  
Upstate Clinical Research, Albany  
Village Clinical Research, New York City  
Weill Cornell Medical Center, New York City  
Zucker Hillside Hospital, Glen Oaks

## Stroke—Leading Institutions Conducting Clinical Trials

Albany Medical Center, Albany  
Burke Medical Research Institute, White Plains  
Columbia Presbyterian Hospital, New York City  
Columbia University Medical Center, New York City  
Lenox Hill Hospital, New York City  
Millard Fillmore Gates Hospital, Buffalo  
Mount Sinai School of Medicine, New York City  
New York Methodist Hospital, Brooklyn  
New York University Medical Center, New York City  
Southtowns Neurology of Western New York, West  
Seneca  
St. Francis Hospital, Roslyn  
SUNY Buffalo, Buffalo  
SUNY Downstate, Brooklyn  
University of Rochester-Strong Memorial Hospital,  
Rochester  
Weill Cornell Medical College, New York

# Appendix

The clinical trials listed here involve tests that have not yet started recruiting patients or are just now seeking volunteers to participate. This information is potentially valuable to patients still seeking effective treatments for their chronic diseases. It provides a new therapeutic option to discuss with physicians.

Those interested in obtaining more information about certain trials can use the URL code listed for each test to log onto [www.clinicaltrials.gov](http://www.clinicaltrials.gov), the clinical tests database of the National Institutes of Health.

## Asthma

(12 clinical trials recruiting)

### Study 1:

**A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids**

<http://ClinicalTrials.gov/show/NCT01479621>

### Study 2:

**A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications**

<http://ClinicalTrials.gov/show/NCT01576718>

### Study 3:

**Safety of QMF149 Twisthaler® in Adolescent and Adult Patients With Asthma**

<http://ClinicalTrials.gov/show/NCT00941798>

### Study 4:

**A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations and Change in Lung Function in Patients (12-75 Years of Age) With Eosinophilic Asthma**

<http://ClinicalTrials.gov/show/NCT01287039>

### Study 5:

**A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma**

<http://ClinicalTrials.gov/show/NCT00809757>

### Study 6:

**A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma**

<http://ClinicalTrials.gov/show/NCT01402986>

### Study 7:

**A Study of Lebrikizumab in Patients Whose Asthma is Uncontrolled With Inhaled Corticosteroids and A Second Controller Medication (LUTE)**

<http://ClinicalTrials.gov/show/NCT01545440>

### Study 8:

**A Study of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and A Second Controller Medication (VERSE)**

<http://ClinicalTrials.gov/show/NCT01545453>

### Study 9:

**Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease**

<http://ClinicalTrials.gov/show/NCT00642616>

### Study 10:

**New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day**

<http://ClinicalTrials.gov/show/NCT01360021>

### Study 11:

**Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis**

<http://ClinicalTrials.gov/show/NCT01008423>

### Study 12:

**Efficacy and Safety of Budesonide Foam for Patients With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis**

<http://ClinicalTrials.gov/show/NCT01008410>

## Cancer

(481 clinical trials recruiting)

### Study 1:

**Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer**

<http://ClinicalTrials.gov/show/NCT00807859>

### Study 2:

**Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium**

<http://ClinicalTrials.gov/show/NCT00896454>

### Study 3:

**Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy**

<http://ClinicalTrials.gov/show/NCT00858364>

### Study 4:

**Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy**

<http://ClinicalTrials.gov/show/NCT00676507>

### Study 5:

**Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer**

<http://ClinicalTrials.gov/show/NCT01453153>

### Study 6:

**A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy**

<http://ClinicalTrials.gov/show/NCT01168973>

### Study 7:

**Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01217697>

### Study 8:

**A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy**

<http://ClinicalTrials.gov/show/NCT00925600>

### Study 9:

**Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01431391>

### Study 10:

**Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)**

<http://ClinicalTrials.gov/show/NCT01077154>

### Study 11:

#### Study of PX-866 and Docetaxel in Solid Tumors

<http://ClinicalTrials.gov/show/NCT01204099>

### Study 12:

#### PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

<http://ClinicalTrials.gov/show/NCT00911170>

### Study 13:

#### A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy

<http://ClinicalTrials.gov/show/NCT01478594>

### Study 14:

#### ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

<http://ClinicalTrials.gov/show/NCT01244191>

### Study 15:

#### A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

<http://ClinicalTrials.gov/show/NCT01400555>

### Study 16:

#### A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

<http://ClinicalTrials.gov/show/NCT00338286>

### Study 17:

#### Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

<http://ClinicalTrials.gov/show/NCT01020006>

### Study 18:

#### The BEACON Study (Breast Cancer Outcomes With NKTR-102)

<http://ClinicalTrials.gov/show/NCT01492101>

### Study 19:

#### Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

<http://ClinicalTrials.gov/show/NCT00045968>

### Study 20:

#### Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

<http://ClinicalTrials.gov/show/NCT01200992>

### Study 21:

#### Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug

<http://ClinicalTrials.gov/show/NCT00988936>

### Study 22:

#### A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer

<http://ClinicalTrials.gov/show/NCT01246960>

### Study 23:

#### Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

<http://ClinicalTrials.gov/show/NCT01439282>

### Study 24:

#### A Study of Onartuzumab (MetMab) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

<http://ClinicalTrials.gov/show/NCT01456325>

### Study 25:

#### A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

<http://ClinicalTrials.gov/show/NCT01288911>

### **Study 26:**

**A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01358877>

### **Study 27:**

**A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)**

<http://ClinicalTrials.gov/show/NCT01120184>

### **Study 28:**

**Efficacy and Safety of Zoledronic Acid (Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer**

<http://ClinicalTrials.gov/show/NCT00320710>

### **Study 29:**

**Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01186991>

### **Study 30:**

**Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer**

<http://ClinicalTrials.gov/show/NCT01416038>

### **Study 31:**

**A Study of Alpharadin® With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)**

<http://ClinicalTrials.gov/show/NCT01106352>

### **Study 32:**

**Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01284348>

### **Study 33:**

**A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01322490>

### **Study 34:**

**Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic**

<http://ClinicalTrials.gov/show/NCT00696072>

### **Study 35:**

**Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01415960>

### **Study 36:**

**A Study in Second Line Metastatic Colorectal Cancer**

<http://ClinicalTrials.gov/show/NCT01183780>

### **Study 37:**

**IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen**

<http://ClinicalTrials.gov/show/NCT01314118>

### **Study 38:**

**Immunotherapy Study for Surgically Resected Pancreatic Cancer**

<http://ClinicalTrials.gov/show/NCT01072981>

### **Study 39:**

**Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer**

<http://ClinicalTrials.gov/show/NCT01395017>

### **Study 40:**

**Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer**

<http://ClinicalTrials.gov/show/NCT01361607>

#### **Study 41:**

**Study of REOLYSIN® in Combination With FOLFIRI in Patients With Oxaliplatin Refractory/Intolerant KRAS Mutant Colorectal Cancer**

<http://ClinicalTrials.gov/show/NCT01274624>

#### **Study 42:**

**Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01528345>

#### **Study 43:**

**A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01427933>

#### **Study 44:**

**Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer**

<http://ClinicalTrials.gov/show/NCT00876395>

#### **Study 45:**

**Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain**

<http://ClinicalTrials.gov/show/NCT01337089>

#### **Study 46:**

**Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients**

<http://ClinicalTrials.gov/show/NCT01234402>

#### **Study 47:**

**A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer**

<http://ClinicalTrials.gov/show/NCT01454089>

#### **Study 48:**

**Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)**

<http://ClinicalTrials.gov/show/NCT01234025>

#### **Study 49:**

**A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy**

<http://ClinicalTrials.gov/show/NCT01381874>

#### **Study 50:**

**A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01234311>

#### **Study 51:**

**Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01057810>

#### **Study 52:**

**Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/FOLFIRI With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer**

<http://ClinicalTrials.gov/show/NCT01374425>

#### **Study 53:**

**Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01193244>

#### **Study 54:**

**Study of Immunotherapy to Treat Advanced Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT00861614>

#### **Study 55:**

**Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01193257>



### **Study 56:**

#### **Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer**

<http://ClinicalTrials.gov/show/NCT00733850>

### **Study 57:**

#### **Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01177397>

### **Study 58:**

#### **A Trial of E7080(Lenvatinib) in 131I-Refractory Differentiated Thyroid Cancer**

<http://ClinicalTrials.gov/show/NCT01321554>

### **Study 59:**

#### **Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01297491>

### **Study 60:**

#### **Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT00686959>

### **Study 61:**

#### **An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)**

<http://ClinicalTrials.gov/show/NCT00829166>

### **Study 62:**

#### **A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01491737>

### **Study 63:**

#### **A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)**

<http://ClinicalTrials.gov/show/NCT01419197>

### **Study 64:**

#### **TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer**

<http://ClinicalTrials.gov/show/NCT01204749>

### **Study 65:**

#### **Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01522443>

### **Study 66:**

#### **A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours**

<http://ClinicalTrials.gov/show/NCT01578239>

### **Study 67:**

#### **NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer**

<http://ClinicalTrials.gov/show/NCT00856375>

### **Study 68:**

#### **Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01113970>

### **Study 69:**

#### **Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01326481>



### **Study 70:**

**Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)**

<http://ClinicalTrials.gov/show/NCT01469221>

### **Study 71:**

**A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung**

<http://ClinicalTrials.gov/show/NCT01154140>

### **Study 72:**

**Safety and Tolerability Study of MDV3100 in Combination With Docetaxel in Men With Advanced Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01565928>

### **Study 73:**

**A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine for 3rd Line Treatment of Patients With Metastatic Pancreatic Cancer**

<http://ClinicalTrials.gov/show/NCT01510561>

### **Study 74:**

**Safety and Tolerability of DS-7423 in Subjects With Advanced Solid Malignant Tumors**

<http://ClinicalTrials.gov/show/NCT01364844>

### **Study 75:**

**Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01007942>

### **Study 76:**

**Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene**

<http://ClinicalTrials.gov/show/NCT01221077>

### **Study 77:**

**Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01234337>

### **Study 78:**

**Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01211483>

### **Study 79:**

**Safety Study of Denosumab in Subjects With Recurrent or Unresectable Giant Cell Tumor of Bone**

<http://ClinicalTrials.gov/show/NCT00680992>

### **Study 80:**

**Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)**

<http://ClinicalTrials.gov/show/NCT01171898>

### **Study 81:**

**Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors**

<http://ClinicalTrials.gov/show/NCT01421004>

### **Study 82:**

**A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Advanced Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01228760>

### **Study 83:**

**Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin**

<http://ClinicalTrials.gov/show/NCT00958841>

### **Study 84:**

**A Phase 1b Study of MDX-1106 in Subjects With Advanced or Recurrent Malignancies**

<http://ClinicalTrials.gov/show/NCT00730639>

### **Study 85:**

**Multi-arm Study of BMS-936558 in Combination With 3 Platinum-based Doublet Chemotherapy Regimens in Subjects With Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01454102>

### **Study 86:**

**Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours**

<http://ClinicalTrials.gov/show/NCT00979134>

### **Study 87:**

**Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)**

<http://ClinicalTrials.gov/show/NCT01355484>

### **Study 88:**

**Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum**

<http://ClinicalTrials.gov/show/NCT01355497>

### **Study 89:**

**A Study in Head and Neck Cancer**

<http://ClinicalTrials.gov/show/NCT01081041>

### **Study 90:**

**Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)**

<http://ClinicalTrials.gov/show/NCT01499043>

### **Study 91:**

**A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4**

<http://ClinicalTrials.gov/show/NCT01409135>

### **Study 92:**

**Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1**

<http://ClinicalTrials.gov/show/NCT01234012>

### **Study 93:**

**Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases**

<http://ClinicalTrials.gov/show/NCT01441596>

### **Study 94:**

**Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01296243>

### **Study 95:**

**Phase 3 Study of ProstAtak™ With Standard Radiation Therapy for Localized Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01436968>

### **Study 96:**

**TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)**

<http://ClinicalTrials.gov/show/NCT01194960>

### **Study 97:**

**Trial of Gemcitabine With or Without Baviximab in Patients With Previously Untreated Stage IV Pancreatic Cancer**

<http://ClinicalTrials.gov/show/NCT01272791>

### **Study 98:**

**Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients**

<http://ClinicalTrials.gov/show/NCT01487785>

### **Study 99:**

**Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer**

<http://ClinicalTrials.gov/show/NCT01270698>

### **Study 100:**

**Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)**

<http://ClinicalTrials.gov/show/NCT01170650>

### **Study 101:**

**MRI/TRUS Fusion Guided Prostate Biopsy—An Improved Way to Detect and Quantify Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01566045>

### **Study 102:**

**Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression**

<http://ClinicalTrials.gov/show/NCT01111461>

### **Study 103:**

**Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT00706862>

### **Study 104:**

**Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01007890>

### **Study 105:**

**A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01268059>

### **Study 106:**

**Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients**

<http://ClinicalTrials.gov/show/NCT01402401>

### **Study 107:**

**A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01362400>

### **Study 108:**

**Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01269346>

### **Study 109:**

**A Study of Trastuzumab-MCC-DM1, Paclitaxel, and Pertuzumab in Patients With HER2-Positive, Locally Advanced or Metastatic Breast Cancer**

<http://ClinicalTrials.gov/show/NCT00951665>

### **Study 110:**

**Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab**

<http://ClinicalTrials.gov/show/NCT01132664>

### **Study 111:**

**A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1**

<http://ClinicalTrials.gov/show/NCT00948961>

### **Study 112:**

**A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population**

<http://ClinicalTrials.gov/show/NCT01313663>

### **Study 113:**

**Safety Study of Live Bacteria to Treat Solid Tumors That Have Not Responded to Standard Therapy**

<http://ClinicalTrials.gov/show/NCT01118819>

### **Study 114:**

**Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01414283>

### **Study 115:**

**Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01414296>

### **Study 116:**

**Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01491971>

### **Study 117:**

**A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01283373>

### **Study 118:**

**A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer**

<http://ClinicalTrials.gov/show/NCT01337518>

### **Study 119:**

**Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01493843>

### **Study 120:**

**Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging in Men With Prostate Cancer Undergoing Prostatectomy and/or Pelvic Lymph Node Dissection**

<http://ClinicalTrials.gov/show/NCT01572701>

### **Study 121:**

**A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non Small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT00974584>

### **Study 122:**

**A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01351415>

### **Study 123:**

**Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3)**

<http://ClinicalTrials.gov/show/NCT01395914>

### **Study 124:**

**A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors**

<http://ClinicalTrials.gov/show/NCT01325558>

### **Study 125:**

**Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2)**

<http://ClinicalTrials.gov/show/NCT01387282>

### **Study 126:**

**EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer**

<http://ClinicalTrials.gov/show/NCT01485848>

### **Study 127:**

**Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of BMS-663513 in Subjects With Advanced and/or Metastatic Solid Tumors**

<http://ClinicalTrials.gov/show/NCT01471210>

### **Study 128:**

**A Dose-Escalation Study in Participants With Advanced Cancer**

<http://ClinicalTrials.gov/show/NCT01524224>

### **Study 129:**

**A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3**

<http://ClinicalTrials.gov/show/NCT01304524>

### **Study 130:**

**A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer**

<http://ClinicalTrials.gov/show/NCT00927589>

### **Study 131:**

**Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01471197>

### **Study 132:**

**Cancer Vaccines CRS-207 and GVAX Pancreas for Metastatic Pancreatic Adenocarcinoma**

<http://ClinicalTrials.gov/show/NCT01417000>

### **Study 133:**

**A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer**

<http://ClinicalTrials.gov/show/NCT01087970>

### **Study 134:**

**Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients**

<http://ClinicalTrials.gov/show/NCT01363232>

### **Study 135:**

**Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin**

<http://ClinicalTrials.gov/show/NCT01285609>

### **Study 136:**

**ARCHER 1009: A Study Of PF-00299804 (Dacomitinib) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01360554>

### **Study 137:**

**Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)**

<http://ClinicalTrials.gov/show/NCT01295632>

### **Study 138:**

**Tesetaxel as First-line Therapy for Metastatic Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01221870>

### **Study 139:**

**Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma**

<http://ClinicalTrials.gov/show/NCT01479465>

### **Study 140:**

**Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Leukemias and Related Disorders**

<http://ClinicalTrials.gov/show/NCT01380756>

### **Study 141:**

**A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma**

<http://ClinicalTrials.gov/show/NCT01472198>

### **Study 142:**

**Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)**

<http://ClinicalTrials.gov/show/NCT01016769>

### **Study 143:**

**A Study of RO5185426 (Vemurafenib) in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation**

<http://ClinicalTrials.gov/show/NCT01286753>

### **Study 144:**

**A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)**

<http://ClinicalTrials.gov/show/NCT01254630>

### **Study 145:**

**Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer**

<http://ClinicalTrials.gov/show/NCT01360853>

### **Study 146:**

**Study of PF-05212384 (Also Known as PKI-587) Administered Intravenously To Subjects With Solid Tumors**

<http://ClinicalTrials.gov/show/NCT00940498>

### **Study 147:**

**An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+**

<http://ClinicalTrials.gov/show/NCT01116245>

### **Study 148:**

**Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration**

<http://ClinicalTrials.gov/show/NCT00878436>

### **Study 149:**

**Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function**

<http://ClinicalTrials.gov/show/NCT00652626>

### **Study 150:**

**An Efficacy and Safety Study to Assess [18F]-ML-10 in Detecting Response of Tumors to Chemotherapy and Radiation**

<http://ClinicalTrials.gov/show/NCT01260480>

### **Study 151:**

**A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors**

<http://ClinicalTrials.gov/show/NCT01106508>

### **Study 152:**

**Study of TAK-733 in Adult Patients With Advanced Nonhematologic Malignancies**

<http://ClinicalTrials.gov/show/NCT00948467>

### **Study 153:**

**LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment**

<http://ClinicalTrials.gov/show/NCT01125566>

### **Study 154:**

**A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and Folfox in Patients With Previously Untreated Metastatic Colorectal Cancer (CONGO)**

<http://ClinicalTrials.gov/show/NCT01399684>

### **Study 155:**

**Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-intestinal Stromal Tumour**

<http://ClinicalTrials.gov/show/NCT00812240>

### **Study 156:**

**Phase 2 Study of Thermodox as Adjuvant Therapy With Radiofrequency Ablation (RFA) in Treatment of Colorectal Liver Metastases (CRLM)**

<http://ClinicalTrials.gov/show/NCT01464593>

### **Study 157:**

**Irinotecan and Bevacizumab for Recurrent Ovarian Cancer**

<http://ClinicalTrials.gov/show/NCT01091259>

### **Study 158:**

**A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)**

<http://ClinicalTrials.gov/show/NCT01160744>

### **Study 159:**

**A Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors**

<http://ClinicalTrials.gov/show/NCT00268905>

### **Study 160:**

**A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction**

<http://ClinicalTrials.gov/show/NCT01273493>



### **Study 161:**

**ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain**

<http://ClinicalTrials.gov/show/NCT00656305>

### **Study 162:**

**Phase 2 Study of Efficacy and Safety of Apricoxib/ Placebo With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients**

<http://ClinicalTrials.gov/show/NCT00771953>

### **Study 163:**

**A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01454934>

### **Study 164:**

**Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma**

<http://ClinicalTrials.gov/show/NCT00993239>

### **Study 165:**

**Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas**

<http://ClinicalTrials.gov/show/NCT00844649>

### **Study 166:**

**Safety and Tolerability Study of SOR-C13 in Subjects With Advanced Cancers Commonly Known to Express the TRPV6 Channel**

<http://ClinicalTrials.gov/show/NCT01578564>

### **Study 167:**

**A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma**

<http://ClinicalTrials.gov/show/NCT01507168>

### **Study 168:**

**A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors**

<http://ClinicalTrials.gov/show/NCT01231594>

### **Study 169:**

**A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma**

<http://ClinicalTrials.gov/show/NCT01237236>

### **Study 170:**

**A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma**

<http://ClinicalTrials.gov/show/NCT00854152>

### **Study 171:**

**Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer**

<http://ClinicalTrials.gov/show/NCT01312857>

### **Study 172:**

**Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable, Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)**

<http://ClinicalTrials.gov/show/NCT01443078>

### **Study 173:**

**Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01276041>

### **Study 174:**

**Patient Controlled Tissue Expansion for Breast Reconstruction**

<http://ClinicalTrials.gov/show/NCT01425268>

### **Study 175:**

**Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer**

<http://ClinicalTrials.gov/show/NCT01003938>

### **Study 176:**

**Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors**

<http://ClinicalTrials.gov/show/NCT00827177>



### **Study 177:**

**Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors**

<http://ClinicalTrials.gov/show/NCT01447225>

### **Study 178:**

**Dose Escalation, Combination Chemotherapy Safety Study of TL32711, in Subjects With Advanced or Metastatic Solid Tumors**

<http://ClinicalTrials.gov/show/NCT01188499>

### **Study 179:**

**Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET**

<http://ClinicalTrials.gov/show/NCT01374451>

### **Study 180:**

**Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects**

<http://ClinicalTrials.gov/show/NCT01403064>

### **Study 181:**

**Combination of Temozolomide and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer**

<http://ClinicalTrials.gov/show/NCT01025453>

### **Study 182:**

**Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment**

<http://ClinicalTrials.gov/show/NCT01520389>

### **Study 183:**

**Cone Beam Computed Tomography for Breast Imaging**

<http://ClinicalTrials.gov/show/NCT00972413>

### **Study 184:**

**Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma**

<http://ClinicalTrials.gov/show/NCT01381861>

### **Study 185:**

**A Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function**

<http://ClinicalTrials.gov/show/NCT01546519>

### **Study 186:**

**Everolimus Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (Gastro Intestinal or Lung Origin)**

<http://ClinicalTrials.gov/show/NCT01524783>

### **Study 187:**

**Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias**

<http://ClinicalTrials.gov/show/NCT00920140>

### **Study 188:**

**Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies**

<http://ClinicalTrials.gov/show/NCT01182168>

### **Study 189:**

**Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors or Advanced Pancreatic Cancer**

<http://ClinicalTrials.gov/show/NCT01497392>

### **Study 190:**

**A Study of of MORAb-004 in Subjects With Solid Tumors**

<http://ClinicalTrials.gov/show/NCT00847054>

### **Study 191:**

**Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors**

<http://ClinicalTrials.gov/show/NCT00884845>

### **Study 192:**

**A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumor**

<http://ClinicalTrials.gov/show/NCT01248949>

### **Study 193:**

**Gemcitabine, Oxaliplatin and Panitumumab in Kras/ B-raf Wild-Type Biliary Track and Gallbladder Cancer**

<http://ClinicalTrials.gov/show/NCT01308840>

### **Study 194:**

**Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)**

<http://ClinicalTrials.gov/show/NCT01573338>

### **Study 195:**

**Afatinib (BIBW 2992) in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer**

<http://ClinicalTrials.gov/show/NCT01522768>

### **Study 196:**

**Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma**

<http://ClinicalTrials.gov/show/NCT01213472>

### **Study 197:**

**Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer**

<http://ClinicalTrials.gov/show/NCT00917462>

### **Study 198:**

**Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma**

<http://ClinicalTrials.gov/show/NCT01035658>

### **Study 199:**

**Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors**

<http://ClinicalTrials.gov/show/NCT01496534>

### **Study 200:**

**Dose Dense Doxorubicin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer**

<http://ClinicalTrials.gov/show/NCT01328249>

### **Study 201:**

**Study of Ruxolitinib in Pancreatic Cancer Patients**

<http://ClinicalTrials.gov/show/NCT01423604>

### **Study 202:**

**Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium**

<http://ClinicalTrials.gov/show/NCT01293448>

### **Study 203:**

**A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)**

<http://ClinicalTrials.gov/show/NCT01235962>

### **Study 204:**

**Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone**

<http://ClinicalTrials.gov/show/NCT01450761>

### **Study 205:**

**Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer**

<http://ClinicalTrials.gov/show/NCT00583349>

### **Study 206:**

**Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01266018>

### **Study 207:**

**Collection of FUJIFILM's 3Dimensional Mammograms**

<http://ClinicalTrials.gov/show/NCT01542814>

### **Study 208:**

**Cone Beam Computed Tomography for Breast Imaging**

<http://ClinicalTrials.gov/show/NCT01107860>

### **Study 209:**

**Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies**

<http://ClinicalTrials.gov/show/NCT01188252>

### **Study 210:**

**RAD001 Plus Carboplatin in Breast Cancer Patients**

<http://ClinicalTrials.gov/show/NCT01127763>

### **Study 211:**

**Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients**

<http://ClinicalTrials.gov/show/NCT00997022>

### **Study 212:**

**A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours**

<http://ClinicalTrials.gov/show/NCT01281592>

### **Study 213:**

**A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors**

<http://ClinicalTrials.gov/show/NCT01063816>

### **Study 214:**

**An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN™ in Subjects With Cancer Who Also Have Impaired Renal Function**

<http://ClinicalTrials.gov/show/NCT01418677>

### **Study 215:**

**A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)**

<http://ClinicalTrials.gov/show/NCT00648648>

### **Study 216:**

**A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)**

<http://ClinicalTrials.gov/show/NCT01283516>

### **Study 217:**

**Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy**

<http://ClinicalTrials.gov/show/NCT00776594>

### **Study 218:**

**Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma**

<http://ClinicalTrials.gov/show/NCT00515411>

### **Study 219:**

**Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons**

<http://ClinicalTrials.gov/show/NCT00627978>

### **Study 220:**

**Study of Temozolomide, Erlotinib and Cisplatin in Solid Tumors**

<http://ClinicalTrials.gov/show/NCT00998036>

### **Study 221:**

**Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer**

<http://ClinicalTrials.gov/show/NCT01090011>

### **Study 222:**

**Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors**

<http://ClinicalTrials.gov/show/NCT01294670>

### **Study 223:**

**Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194**

<http://ClinicalTrials.gov/show/NCT00820170>

### Study 224:

#### Panitumumab Pediatric Study

<http://ClinicalTrials.gov/show/NCT00658658>

### Study 225:

#### A Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

<http://ClinicalTrials.gov/show/NCT01204164>

### Study 226:

#### Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

<http://ClinicalTrials.gov/show/NCT00567359>

### Study 227:

#### Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

<http://ClinicalTrials.gov/show/NCT01392209>

### Study 228:

#### Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma

<http://ClinicalTrials.gov/show/NCT00588523>

### Study 229:

#### Bevacizumab, Cetuximab, and Cisplatin With IMRT (Intensity-Modulated Radiation Therapy) for Patients With Stage III/IV Head and Neck Squamous Cell Carcinoma

<http://ClinicalTrials.gov/show/NCT00968435>

### Study 230:

#### Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

<http://ClinicalTrials.gov/show/NCT01331824>

### Study 231:

#### A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer

<http://ClinicalTrials.gov/show/NCT01114230>

### Study 232:

#### Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma

<http://ClinicalTrials.gov/show/NCT01105702>

### Study 233:

#### Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

<http://ClinicalTrials.gov/show/NCT01192165>

### Study 234:

#### Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

<http://ClinicalTrials.gov/show/NCT00776867>

### Study 235:

#### Multiple Ascending Dose of BMS-911543

<http://ClinicalTrials.gov/show/NCT01236352>

### Study 236:

#### Tesetaxel for Previously Treated Patients With Bladder Cancer

<http://ClinicalTrials.gov/show/NCT01215877>

### Study 237:

#### BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)

<http://ClinicalTrials.gov/show/NCT01453595>

### Study 238:

#### RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

<http://ClinicalTrials.gov/show/NCT01259063>

### Study 239:

#### Multiple Ascending Dose (MDX1105-01)

<http://ClinicalTrials.gov/show/NCT00729664>

### Study 240:

#### A Study of the Safety, Tolerability, and Efficacy of SCH 900353 in Participants With Advanced Solid Tumors (P06203 AM2)

<http://ClinicalTrials.gov/show/NCT01358331>

### **Study 241:**

**Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma**

<http://ClinicalTrials.gov/show/NCT00132301>

### **Study 242:**

**Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess**

<http://ClinicalTrials.gov/show/NCT00994110>

### **Study 243:**

**Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors**

<http://ClinicalTrials.gov/show/NCT01049841>

### **Study 244:**

**Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse**

<http://ClinicalTrials.gov/show/NCT01217203>

### **Study 245:**

**A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver**

<http://ClinicalTrials.gov/show/NCT00906373>

### **Study 246:**

**BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors**

<http://ClinicalTrials.gov/show/NCT01297452>

### **Study 247:**

**Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer**

<http://ClinicalTrials.gov/show/NCT00217477>

### **Study 248:**

**A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer**

<http://ClinicalTrials.gov/show/NCT00670189>

### **Study 249:**

**A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer**

<http://ClinicalTrials.gov/show/NCT01262651>

### **Study 250:**

**A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts**

<http://ClinicalTrials.gov/show/NCT01007552>

### **Study 251:**

**A Study Of Panobinostat In Children With Refractory Hematologic Malignancies**

<http://ClinicalTrials.gov/show/NCT01321346>

### **Study 252:**

**Dalteparin in Combination With Sunitinib in Patients With Metastatic Kidney Cancer**

<http://ClinicalTrials.gov/show/NCT01061411>

### **Study 253:**

**Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation**

<http://ClinicalTrials.gov/show/NCT01514864>

### **Study 254:**

**A Safety Study of LBH589 (Panobinostat) and RAD001 (Everolimus) to Stabilize Kidney Cancer**

<http://ClinicalTrials.gov/show/NCT01037257>

### **Study 255:**

**Pharmacokinetic and Safety Study of Paclitaxel Injection Concentrate for Nano-dispersion Alone and in Combination With Carboplatin**

<http://ClinicalTrials.gov/show/NCT01304303>

### **Study 256:**

**Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain**

<http://ClinicalTrials.gov/show/NCT01384292>

### **Study 257:**

**Pharmacokinetic, Safety and Tolerability Study of Paclitaxel Injection Concentrate for Nano-dispersion Administered Weekly**

<http://ClinicalTrials.gov/show/NCT01305512>

### **Study 258:**

**Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers**

<http://ClinicalTrials.gov/show/NCT01166542>

### **Study 259:**

**Phase 1 and 2 Study of PX-866 and Cetuximab**

<http://ClinicalTrials.gov/show/NCT01252628>

### **Study 260:**

**CBLB502 in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery**

<http://ClinicalTrials.gov/show/NCT01527136>

### **Study 261:**

**Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease**

<http://ClinicalTrials.gov/show/NCT00690430>

### **Study 262:**

**Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence**

<http://ClinicalTrials.gov/show/NCT01178281>

### **Study 263:**

**Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01183949>

### **Study 264:**

**PF-00299804 As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung**

<http://ClinicalTrials.gov/show/NCT00818441>

### **Study 265:**

**A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab**

<http://ClinicalTrials.gov/show/NCT01307267>

### **Study 266:**

**Study to Evaluate Efficacy of CO-1.01 as Second Line Therapy for Gemcitabine-Refractory Stage IV Pancreatic Adenocarcinoma**

<http://ClinicalTrials.gov/show/NCT01233375>

### **Study 267:**

**A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer**

<http://ClinicalTrials.gov/show/NCT01304784>

### **Study 268:**

**HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer**

<http://ClinicalTrials.gov/show/NCT01387932>

### **Study 269:**

**An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study**

<http://ClinicalTrials.gov/show/NCT01090414>

### **Study 270:**

**A Study of the Safety and Efficacy of ONO-7746 in Adult Cancer Patients With Chemotherapy Induced Thrombocytopenia**

<http://ClinicalTrials.gov/show/NCT01345214>

### **Study 271:**

**Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma)**

<http://ClinicalTrials.gov/show/NCT00976170>

### **Study 272:**

**A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients**

<http://ClinicalTrials.gov/show/NCT00876915>



### **Study 273:**

**A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred**

<http://ClinicalTrials.gov/show/NCT00691210>

### **Study 274:**

**Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies**

<http://ClinicalTrials.gov/show/NCT00504972>

### **Study 275:**

**Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies**

<http://ClinicalTrials.gov/show/NCT00672165>

### **Study 276:**

**IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma**

<http://ClinicalTrials.gov/show/NCT01265901>

### **Study 277:**

**F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets**

<http://ClinicalTrials.gov/show/NCT00882609>

### **Study 278:**

**Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder, Urethra, Ureter, or Renal Pelvis Carcinoma**

<http://ClinicalTrials.gov/show/NCT01282463>

### **Study 279:**

**A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma**

<http://ClinicalTrials.gov/show/NCT01455493>

### **Study 280:**

**A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung**

<http://ClinicalTrials.gov/show/NCT01218516>

### **Study 281:**

**A Dose Finding and Safety Study of Oral LDE225 in Children**

<http://ClinicalTrials.gov/show/NCT01125800>

### **Study 282:**

**Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01001442>

### **Study 283:**

**Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients**

<http://ClinicalTrials.gov/show/NCT01430416>

### **Study 284:**

**DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma**

<http://ClinicalTrials.gov/show/NCT01353222>

### **Study 285:**

**A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung**

<http://ClinicalTrials.gov/show/NCT00998192>

### **Study 286:**

**Study of ACE-041 in Patients With Squamous Cell Carcinoma of the Head and Neck**

<http://ClinicalTrials.gov/show/NCT01458392>

### **Study 287:**

**Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients**

<http://ClinicalTrials.gov/show/NCT01121120>

### **Study 288:**

**Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)**

<http://ClinicalTrials.gov/show/NCT00916409>



### **Study 289:**

**Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01239797>

### **Study 290:**

**Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01335399>

### **Study 291:**

**Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01478048>

### **Study 292:**

**IMGN901 in Combination With Lenalidomide and Dexamethasone**

<http://ClinicalTrials.gov/show/NCT00991562>

### **Study 293:**

**Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function**

<http://ClinicalTrials.gov/show/NCT01393964>

### **Study 294:**

**Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma**

<http://ClinicalTrials.gov/show/NCT01441973>

### **Study 295:**

**An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study**

<http://ClinicalTrials.gov/show/NCT00947856>

### **Study 296:**

**Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma**

<http://ClinicalTrials.gov/show/NCT01223027>

### **Study 297:**

**Study of Oral MLN9708 in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01383928>

### **Study 298:**

**Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01323751>

### **Study 299:**

**A Study of MLN9708 Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01217957>

### **Study 300:**

**Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)**

<http://ClinicalTrials.gov/show/NCT01191801>

### **Study 301:**

**Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral MLN9708 in Adult Patients With Relapsed and Refractory Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT00963820>

### **Study 302:**

**A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01248923>

### **Study 303:**

**Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients**

<http://ClinicalTrials.gov/show/NCT01002248>

### **Study 304:**

**A Study of Siltuximab (Anti-IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01484275>

### **Study 305:**

**Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01478581>

### **Study 306:**

**Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01302886>

### **Study 307:**

**A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease**

<http://ClinicalTrials.gov/show/NCT01458288>

### **Study 308:**

**A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma**

<http://ClinicalTrials.gov/show/NCT01349036>

### **Study 309:**

**Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)**

<http://ClinicalTrials.gov/show/NCT00617981>

### **Study 310:**

**Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma**

<http://ClinicalTrials.gov/show/NCT01480479>

### **Study 311:**

**Safety Study of Adjuvant Vaccine to Treat Melanoma Patients**

<http://ClinicalTrials.gov/show/NCT01079741>

### **Study 312:**

**RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma**

<http://ClinicalTrials.gov/show/NCT01252251>

### **Study 313:**

**First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma**

<http://ClinicalTrials.gov/show/NCT01215136>

### **Study 314:**

**Cabazitaxel—PF Induction Chemotherapy**

<http://ClinicalTrials.gov/show/NCT01379339>

### **Study 315:**

**A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)**

<http://ClinicalTrials.gov/show/NCT01124786>

### **Study 316:**

**Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma**

<http://ClinicalTrials.gov/show/NCT01492673>

### **Study 317:**

**Efficacy and Safety of BC-819 and Gemcitabine Versus Gemcitabine Alone in Treatment-Naive Patients With Locally Advanced Pancreatic Adenocarcinoma**

<http://ClinicalTrials.gov/show/NCT01413087>

### **Study 318:**

**Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia**

<http://ClinicalTrials.gov/show/NCT01471782>

### **Study 319:**

**MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation**

<http://ClinicalTrials.gov/show/NCT01380145>

### **Study 320:**

**Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia**

<http://ClinicalTrials.gov/show/NCT01158885>

### Study 321:

**Gemcitabine, Cisplatin, Plus Lenalidomide as First-line Therapy for Patients With Metastatic Urothelial Carcinoma**

<http://ClinicalTrials.gov/show/NCT01342172>

### Study 322:

**A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma**

<http://ClinicalTrials.gov/show/NCT01498328>

### Study 323:

**Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia**

<http://ClinicalTrials.gov/show/NCT01351935>

### Study 324:

**Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma**

<http://ClinicalTrials.gov/show/NCT00301418>

### Study 325:

**Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01029054>

### Study 326:

**Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT01014208>

### Study 327:

**Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide**

<http://ClinicalTrials.gov/show/NCT01432600>

### Study 328:

**Lenalidomide Plus Melphalan as a Preparative Regimen for Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma: A Phase 1 / 2 Study**

<http://ClinicalTrials.gov/show/NCT01054196>

### Study 329:

**A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma**

<http://ClinicalTrials.gov/show/NCT01310816>

### Study 330:

**Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65**

<http://ClinicalTrials.gov/show/NCT01208662>

### Study 331:

**Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01351623>

### Study 332:

**Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT00538733>

### Study 333:

**Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01146834>

### Study 334:

**Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01559935>

### Study 335:

**Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions**

<http://ClinicalTrials.gov/show/NCT01131169>

### Study 336:

**Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma**

<http://ClinicalTrials.gov/show/NCT01315873>

### **Study 337:**

**Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma**

<http://ClinicalTrials.gov/show/NCT01159574>

### **Study 338:**

**A Study to Evaluate the Use of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Multiple Myeloma**

<http://ClinicalTrials.gov/show/NCT01438177>

### **Study 339:**

**Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600EBRAF Mutation**

<http://ClinicalTrials.gov/show/NCT01474551>

### **Study 340:**

**A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)**

<http://ClinicalTrials.gov/show/NCT01369329>

### **Study 341:**

**Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma**

<http://ClinicalTrials.gov/show/NCT01339052>

### **Study 342:**

**Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma**

<http://ClinicalTrials.gov/show/NCT01032070>

### **Study 343:**

**Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)**

<http://ClinicalTrials.gov/show/NCT00585312>

### **Study 344:**

**A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)**

<http://ClinicalTrials.gov/show/NCT01280552>

### **Study 345:**

**A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib**

<http://ClinicalTrials.gov/show/NCT01140347>

### **Study 346:**

**Efficacy Study of Pharmacokinetic(PK)/ Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma**

<http://ClinicalTrials.gov/show/NCT01335009>

### **Study 347:**

**Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma**

<http://ClinicalTrials.gov/show/NCT01435369>

### **Study 348:**

**A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma**

<http://ClinicalTrials.gov/show/NCT01343277>

### **Study 349:**

**A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment**

<http://ClinicalTrials.gov/show/NCT01136733>

### **Study 350:**

**Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia**

<http://ClinicalTrials.gov/show/NCT00782067>

### **Study 351:**

**Ph I/II Ipilimumab Vemurafenib Combo**

<http://ClinicalTrials.gov/show/NCT01400451>

### **Study 352:**

**Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma**

<http://ClinicalTrials.gov/show/NCT01024231>

### **Study 353:**

**BMS-936558 (MDX-1106) In Combination With Sunitinib or Pazopanib in Subjects With Metastatic Renal Cell Carcinoma (RCC)**

<http://ClinicalTrials.gov/show/NCT01472081>

### **Study 354:**

**Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma**

<http://ClinicalTrials.gov/show/NCT01124539>

### **Study 355:**

**A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas**

<http://ClinicalTrials.gov/show/NCT00704080>

### **Study 356:**

**Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC**

<http://ClinicalTrials.gov/show/NCT00908752>

### **Study 357:**

**Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)**

<http://ClinicalTrials.gov/show/NCT01265576>

### **Study 358:**

**ADI-PEG 20 Versus Placebo in Subjects With Advanced Hepatocellular Carcinoma Who Have Failed Prior Systemic Therapy**

<http://ClinicalTrials.gov/show/NCT01287585>

### **Study 359:**

**A Study of LY2157299 in Patients With Hepatocellular Carcinoma**

<http://ClinicalTrials.gov/show/NCT01246986>

### **Study 360:**

**A Study of RO5185426 And GDC-0973 in Patients With BRAF-Mutation Positive Metastatic Melanoma**

<http://ClinicalTrials.gov/show/NCT01271803>

### **Study 361:**

**A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations**

<http://ClinicalTrials.gov/show/NCT01519323>

### **Study 362:**

**An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma**

<http://ClinicalTrials.gov/show/NCT01136967>

### **Study 363:**

**Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab**

<http://ClinicalTrials.gov/show/NCT01515189>

### **Study 364:**

**Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma**

<http://ClinicalTrials.gov/show/NCT01282424>

### **Study 365:**

**Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma**

<http://ClinicalTrials.gov/show/NCT01168791>

### **Study 366:**

**Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma**

<http://ClinicalTrials.gov/show/NCT01327885>

### **Study 367:**

**NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed**

<http://ClinicalTrials.gov/show/NCT01098266>

### **Study 368:**

**A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma**

<http://ClinicalTrials.gov/show/NCT01327053>

### **Study 369:**

**Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL**

<http://ClinicalTrials.gov/show/NCT00546793>

### **Study 370:**

**A Study of IMC-3G3 in Soft Tissue Sarcoma**

<http://ClinicalTrials.gov/show/NCT01185964>

### **Study 371:**

**A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)**

<http://ClinicalTrials.gov/show/NCT01377922>

### **Study 372:**

**A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma**

<http://ClinicalTrials.gov/show/NCT00998322>

### **Study 373:**

**A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma**

<http://ClinicalTrials.gov/show/NCT01440088>

### **Study 374:**

**Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free**

<http://ClinicalTrials.gov/show/NCT01141491>

### **Study 375:**

**Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas**

<http://ClinicalTrials.gov/show/NCT00782626>

### **Study 376:**

**Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma**

<http://ClinicalTrials.gov/show/NCT01025089>

### **Study 377:**

**Study Using Chemotherapy +/- Pleurectomy/Decortication Followed By Intensity Modulated Radiation Therapy**

<http://ClinicalTrials.gov/show/NCT00715611>

### **Study 378:**

**BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma**

<http://ClinicalTrials.gov/show/NCT01034631>

### **Study 379:**

**Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)**

<http://ClinicalTrials.gov/show/NCT01349049>

### **Study 380:**

**A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy**

<http://ClinicalTrials.gov/show/NCT01232556>

### **Study 381:**

**A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)**

<http://ClinicalTrials.gov/show/NCT01100502>

### **Study 382:**

**A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL)**

<http://ClinicalTrials.gov/show/NCT01087151>

### **Study 383:**

**Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide**

<http://ClinicalTrials.gov/show/NCT00629343>

### **Study 384:**

**Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2**

<http://ClinicalTrials.gov/show/NCT01419639>



### **Study 385:**

**Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas**

<http://ClinicalTrials.gov/show/NCT01338857>

### **Study 386:**

**Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma**

<http://ClinicalTrials.gov/show/NCT01114555>

### **Study 387:**

**Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)**

<http://ClinicalTrials.gov/show/NCT01399918>

### **Study 388:**

**Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes**

<http://ClinicalTrials.gov/show/NCT00887809>

### **Study 389:**

**Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity**

<http://ClinicalTrials.gov/show/NCT01323517>

### **Study 390:**

**Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma**

<http://ClinicalTrials.gov/show/NCT00788775>

### **Study 391:**

**Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy**

<http://ClinicalTrials.gov/show/NCT01242488>

### **Study 392:**

**A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell CLL Following Second Line Therapy (THE CONTINUUM TRIAL)**

<http://ClinicalTrials.gov/show/NCT00774345>

### **Study 393:**

**Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia**

<http://ClinicalTrials.gov/show/NCT01460160>

### **Study 394:**

**Safety and Efficacy Study of Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT01325701>

### **Study 395:**

**Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts**

<http://ClinicalTrials.gov/show/NCT01241500>

### **Study 396:**

**Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)**

<http://ClinicalTrials.gov/show/NCT01147939>

### **Study 397:**

**Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant**

<http://ClinicalTrials.gov/show/NCT01321541>

### **Study 398:**

**Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT01482962>

### **Study 399:**

**Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome**

<http://ClinicalTrials.gov/show/NCT00127881>

### **Study 400:**

**BKM120 in Metastatic Transitional Cell Carcinoma of the Urothelium**

<http://ClinicalTrials.gov/show/NCT01551030>

### **Study 401:**

**Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia**

<http://ClinicalTrials.gov/show/NCT00963105>

### **Study 402:**

**Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)**

<http://ClinicalTrials.gov/show/NCT00910910>

### **Study 403:**

**A Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)**

<http://ClinicalTrials.gov/show/NCT01261312>

### **Study 404:**

**A Phase I Study of GNKG186 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)**

<http://ClinicalTrials.gov/show/NCT01035216>

### **Study 405:**

**Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients**

<http://ClinicalTrials.gov/show/NCT00931918>

### **Study 406:**

**Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia**

<http://ClinicalTrials.gov/show/NCT01088048>

### **Study 407:**

**A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT01414855>

### **Study 408:**

**Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)**

<http://ClinicalTrials.gov/show/NCT01073163>

### **Study 409:**

**Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients**

<http://ClinicalTrials.gov/show/NCT00590187>

### **Study 410:**

**A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia**

<http://ClinicalTrials.gov/show/NCT01303796>

### **Study 411:**

**PD0332991 in Patients With Advanced or Metastatic Liposarcoma**

<http://ClinicalTrials.gov/show/NCT01209598>

### **Study 412:**

**Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B Cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT01197560>

### **Study 413:**

**Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL**

<http://ClinicalTrials.gov/show/NCT01101581>

### **Study 414:**

**Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia**

<http://ClinicalTrials.gov/show/NCT01188681>

### **Study 415:**

**Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma**

<http://ClinicalTrials.gov/show/NCT01492088>

### **Study 416:**

**Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)**

<http://ClinicalTrials.gov/show/NCT01295710>

### **Study 417:**

**A Study to Assess AC220 Given in Combination With Induction and Consolidation Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML)**

<http://ClinicalTrials.gov/show/NCT01390337>

### **Study 418:**

**A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma**

<http://ClinicalTrials.gov/show/NCT01569750>

### **Study 419:**

**Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101) in Relapsed or Refractory Hodgkin Lymphoma**

<http://ClinicalTrials.gov/show/NCT01393106>

### **Study 420:**

**Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine**

<http://ClinicalTrials.gov/show/NCT01519011>

### **Study 421:**

**Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma**

<http://ClinicalTrials.gov/show/NCT01363817>

### **Study 422:**

**An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment**

<http://ClinicalTrials.gov/show/NCT00980018>

### **Study 423:**

**Ofatumumab and Bendamustine Combination Therapy Compared With Bendamustine Monotherapy in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) Unresponsive to Rituximab or a Rituximab-Containing Regimen**

<http://ClinicalTrials.gov/show/NCT01077518>

### **Study 424:**

**A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial**

<http://ClinicalTrials.gov/show/NCT00737529>

### **Study 425:**

**A Study of CAL-101 and Rituximab in Elderly Patients With Untreated CLL or SLL**

<http://ClinicalTrials.gov/show/NCT01203930>

### **Study 426:**

**A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib**

<http://ClinicalTrials.gov/show/NCT00777036>

### **Study 427:**

**Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy**

<http://ClinicalTrials.gov/show/NCT00790036>

### **Study 428:**

**Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects**

<http://ClinicalTrials.gov/show/NCT01177540>

### **Study 429:**

**Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT01402440>

### **Study 430:**

**Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT01134341>

### **Study 431:**

**Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)**

<http://ClinicalTrials.gov/show/NCT00854646>

### **Study 432:**

**Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma**

<http://ClinicalTrials.gov/show/NCT00998946>

### **Study 433:**

**A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).**

<http://ClinicalTrials.gov/show/NCT00946647>

### **Study 434:**

**A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)**

<http://ClinicalTrials.gov/show/NCT01300247>

### **Study 435:**

**A Study of Escalating Doses of DCDS4501A in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia**

<http://ClinicalTrials.gov/show/NCT01290549>

### **Study 436:**

**Study of Plerixafor Combined With Cytarabine and Daunorubicin in Patients With Newly Diagnosed Acute Myeloid Leukemia**

<http://ClinicalTrials.gov/show/NCT00990054>

### **Study 437:**

**Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML—CP (Chronic Myelogenous Leukemia—Chronic Phase)**

<http://ClinicalTrials.gov/show/NCT00718263>

### **Study 438:**

**A Study of MLN9708 in Adult Patients With Lymphoma**

<http://ClinicalTrials.gov/show/NCT00893464>

### **Study 439:**

**Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy**

<http://ClinicalTrials.gov/show/NCT01039376>

### **Study 440:**

**Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients**

<http://ClinicalTrials.gov/show/NCT01420679>

### **Study 441:**

**Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)**

<http://ClinicalTrials.gov/show/NCT01466179>

### **Study 442:**

**Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia**

<http://ClinicalTrials.gov/show/NCT01280786>

### **Study 443:**

**Single Agent Ofatumumab Vs. Single Agent Rituximab in Follicular Lymphoma Relapsed After Rituximab-Containing Therapy**

<http://ClinicalTrials.gov/show/NCT01200589>

### **Study 444:**

**A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment**

<http://ClinicalTrials.gov/show/NCT01007292>

### **Study 445:**

**Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)**

<http://ClinicalTrials.gov/show/NCT01265199>

#### **Study 446:**

**Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)**

<http://ClinicalTrials.gov/show/NCT01397799>

#### **Study 447:**

**Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma**

<http://ClinicalTrials.gov/show/NCT01558661>

#### **Study 448:**

**First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma**

<http://ClinicalTrials.gov/show/NCT01524991>

#### **Study 449:**

**Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL**

<http://ClinicalTrials.gov/show/NCT00981799>

#### **Study 450:**

**A Phase I Study of AC220 for Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia**

<http://ClinicalTrials.gov/show/NCT01411267>

#### **Study 451:**

**A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With HM Receiving Treatment With Anti-CD20 Monoclonal Antibodies (V212-013)**

<http://ClinicalTrials.gov/show/NCT01460719>

#### **Study 452:**

**Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL)**

<http://ClinicalTrials.gov/show/NCT01120834>

#### **Study 453:**

**Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL**

<http://ClinicalTrials.gov/show/NCT00529360>

#### **Study 454:**

**Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT01004991>

#### **Study 455:**

**Combination Veltuzumab and Fractionated 90Y-Epratuzumab Radioimmunotherapy in Follicular Lymphoma**

<http://ClinicalTrials.gov/show/NCT01147393>

#### **Study 456:**

**Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT01484093>

#### **Study 457:**

**Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy**

<http://ClinicalTrials.gov/show/NCT00777114>

#### **Study 458:**

**Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma**

<http://ClinicalTrials.gov/show/NCT01186458>

#### **Study 459:**

**Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT01111188>

#### **Study 460:**

**Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant**

<http://ClinicalTrials.gov/show/NCT01437709>

#### **Study 461:**

**Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma**

<http://ClinicalTrials.gov/show/NCT01508312>

### **Study 462:**

**Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease**

<http://ClinicalTrials.gov/show/NCT01155817>

### **Study 463:**

**Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia**

<http://ClinicalTrials.gov/show/NCT00940524>

### **Study 464:**

**Phase II R-ABVD Versus ABVD for Advanced Stage Classical Hodgkin Lymphoma**

<http://ClinicalTrials.gov/show/NCT00654732>

### **Study 465:**

**Lenalidomide in HTLV-1 Adult T-Cell Leukemia**

<http://ClinicalTrials.gov/show/NCT01274533>

### **Study 466:**

**Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)**

<http://ClinicalTrials.gov/show/NCT00628238>

### **Study 467:**

**Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma**

<http://ClinicalTrials.gov/show/NCT01032148>

### **Study 468:**

**Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML)**

<http://ClinicalTrials.gov/show/NCT01352650>

### **Study 469:**

**Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT01472562>

### **Study 470:**

**A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)**

<http://ClinicalTrials.gov/show/NCT00918463>

### **Study 471:**

**Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)**

<http://ClinicalTrials.gov/show/NCT01199575>

### **Study 472:**

**Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL**

<http://ClinicalTrials.gov/show/NCT01125176>

### **Study 473:**

**Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL**

<http://ClinicalTrials.gov/show/NCT01523977>

### **Study 474:**

**Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma**

<http://ClinicalTrials.gov/show/NCT00712582>

### **Study 475:**

**A Novel Sequential Treatment of Salvage and Reduced Intensity Conditioning (RIC) Chemotherapy for Allogeneic Stem-Cell Transplantation (SCT) for Primary Refractory and Relapsed Acute Myelogenous Leukemia (AML)**

<http://ClinicalTrials.gov/show/NCT00875693>

### **Study 476:**

**Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age**

<http://ClinicalTrials.gov/show/NCT01011894>



### Study 477:

**Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study**

<http://ClinicalTrials.gov/show/NCT00940602>

### Study 478:

**A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp**

<http://ClinicalTrials.gov/show/NCT01541553>

### Study 479:

**A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome**

<http://ClinicalTrials.gov/show/NCT01513317>

### Study 480:

**A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q**

<http://ClinicalTrials.gov/show/NCT01029262>

### Study 481:

**Phase 2 Study of Telintra® in Deletion 5q Myelodysplastic Syndrome**

<http://ClinicalTrials.gov/show/NCT01422486>

## Diabetes

(46 clinical trials recruiting)

### Study 1:

**A Study in Adults With Type 2 Diabetes**

<http://ClinicalTrials.gov/show/NCT01421459>

### Study 2:

**A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin**

<http://ClinicalTrials.gov/show/NCT01570751>

### Study 3:

**Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes**

<http://ClinicalTrials.gov/show/NCT01204775>

### Study 4:

**Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)**

<http://ClinicalTrials.gov/show/NCT01394952>

### Study 5:

**CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes**

<http://ClinicalTrials.gov/show/NCT01243424>

### Study 6:

**A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication**

<http://ClinicalTrials.gov/show/NCT01195662>

### Study 7:

**A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)**

<http://ClinicalTrials.gov/show/NCT01137474>

### Study 8:

**BI 10773 Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients**

<http://ClinicalTrials.gov/show/NCT01131676>

### Study 9:

**Safety and Efficacy of BI 10773 and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes**

<http://ClinicalTrials.gov/show/NCT01289990>

### Study 10:

**Efficacy and Safety of BI 10773/BI 1356 Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients**

<http://ClinicalTrials.gov/show/NCT01422876>

### Study 11:

**Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus**

<http://ClinicalTrials.gov/show/NCT01144338>

### Study 12:

**Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome**

<http://ClinicalTrials.gov/show/NCT00968708>

### Study 13:

**A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone**

<http://ClinicalTrials.gov/show/NCT01434186>

### Study 14:

**Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes**

<http://ClinicalTrials.gov/show/NCT01351675>

### Study 15:

**A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus**

<http://ClinicalTrials.gov/show/NCT01042769>

### Study 16:

**Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus**

<http://ClinicalTrials.gov/show/NCT00789750>

### Study 17:

**Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus**

<http://ClinicalTrials.gov/show/NCT01414920>

### Study 18:

**Evaluate Safety of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder) on Diabetic Subjects With Mild Obstructive Pulmonary Disease**

<http://ClinicalTrials.gov/show/NCT00642616>

### Study 19:

**Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period**

<http://ClinicalTrials.gov/show/NCT01445951>

### Study 20:

**A Trial Investigating the Efficacy and Safety of Insulin Degludec in Children and Adolescents With Type 1 Diabetes Mellitus**

<http://ClinicalTrials.gov/show/NCT01513473>

### Study 21:

**A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes**

<http://ClinicalTrials.gov/show/NCT01474083>

### Study 22:

**A Trial of 18F-AV-133 Positron Emission Tomography (PET)**

<http://ClinicalTrials.gov/show/NCT01515384>

### Study 23:

**A Study in Patients With Type I Diabetes Mellitus**

<http://ClinicalTrials.gov/show/NCT01454284>

### Study 24:

**A Study in Participants With Type 2 Diabetes Mellitus**

<http://ClinicalTrials.gov/show/NCT01468987>

### **Study 25:**

**Efficacy and Safety of Azilsartan Medoxomil Used in Combination With Metformin in Participants With Hypertension and Diabetes**

<http://ClinicalTrials.gov/show/NCT01496430>

### **Study 26:**

**Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug—PF04937319 In Patients With Type 2 Diabetes**

<http://ClinicalTrials.gov/show/NCT01475461>

### **Study 27:**

**A Phase III Study to Evaluate Safety, Tolerability and Efficacy of CureXcell™ in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes Mellitus**

<http://ClinicalTrials.gov/show/NCT01421966>

### **Study 28:**

**A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients**

<http://ClinicalTrials.gov/show/NCT01487109>

### **Study 29:**

**Comparison of Technosphere Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus**

<http://ClinicalTrials.gov/show/NCT01451398>

### **Study 30:**

**AMG 151 Amgen Protocol Number 20100761**

<http://ClinicalTrials.gov/show/NCT01464437>

### **Study 31:**

**Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature**

<http://ClinicalTrials.gov/show/NCT01497938>

### **Study 32:**

**Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients**

<http://ClinicalTrials.gov/show/NCT00995930>

### **Study 33:**

**Exeantide in Type 2 Diabetes on Insulin**

<http://ClinicalTrials.gov/show/NCT01154933>

### **Study 34:**

**Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients**

<http://ClinicalTrials.gov/show/NCT01476475>

### **Study 35:**

**Insulin Resistance Intervention After Stroke Trial**

<http://ClinicalTrials.gov/show/NCT00091949>

### **Study 36:**

**A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy**

<http://ClinicalTrials.gov/show/NCT01488877>

### **Study 37:**

**A Study in Patients With Diabetic Kidney Disease**

<http://ClinicalTrials.gov/show/NCT01113801>

### **Study 38:**

**Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy**

<http://ClinicalTrials.gov/show/NCT01496365>

### **Study 39:**

**Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)**

<http://ClinicalTrials.gov/show/NCT01147250>

### **Study 40:**

**Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain**

<http://ClinicalTrials.gov/show/NCT01455415>

### Study 41:

**A Study to Evaluate the Efficacy and Safety of a Single Application of QUTENZA Compared to That of Placebo in Reducing Pain Intensity in Subjects With Painful Diabetic Peripheral Neuropathy (PDPN)**

<http://ClinicalTrials.gov/show/NCT01533428>

### Study 42:

**Efficacy and Safety Study of Pregabalin in the Treatment of Pain on Walking in Patients With Diabetic Peripheral Neuropathy (DPN)**

<http://ClinicalTrials.gov/show/NCT01474772>

### Study 43:

**A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy**

<http://ClinicalTrials.gov/show/NCT01399580>

### Study 44:

**Use of Topical Lidocaine to Reduce Pain in Patients With Diabetic Neuropathy**

<http://ClinicalTrials.gov/show/NCT01086150>

### Study 45:

**Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers**

<http://ClinicalTrials.gov/show/NCT01353937>

### Study 46:

**Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis**

<http://ClinicalTrials.gov/show/NCT01262898>

## Heart Disease

(50 clinical trials recruiting)

### Study 1:

**A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease**

<http://ClinicalTrials.gov/show/NCT01516541>

### Study 2:

**Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina**

<http://ClinicalTrials.gov/show/NCT01508910>

### Study 3:

**A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery**

<http://ClinicalTrials.gov/show/NCT01245634>

### Study 4:

**A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol**

<http://ClinicalTrials.gov/show/NCT01475825>

### Study 5:

**Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With Implantable Cardioverter Defibrillators (ICDs)**

<http://ClinicalTrials.gov/show/NCT01464476>

### Study 6:

**A Study With Alectinib in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus**

<http://ClinicalTrials.gov/show/NCT01042769>

### Study 7:

**Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)**

<http://ClinicalTrials.gov/show/NCT00683696>

### Study 8:

**Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin**

<http://ClinicalTrials.gov/show/NCT01225562>

### **Study 9:**

**Safety and Efficacy Continued Access Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in Very High Risk Subjects Who Need Aortic Valve Replacement**

<http://ClinicalTrials.gov/show/NCT01531374>

### **Study 10:**

**Clinical Evaluation of the Blazer® Open-Irrigated Catheter for Treatment of Type 1 Atrial Flutter**

<http://ClinicalTrials.gov/show/NCT01253200>

### **Study 11:**

**The Evaluation of VAD InterVENTion Before Inotropic Therapy**

<http://ClinicalTrials.gov/show/NCT01369407>

### **Study 12:**

**Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI**

<http://ClinicalTrials.gov/show/NCT00990327>

### **Study 13:**

**RED-HF™ Trial—Reduction of Events With Darbepoetin Alfa in Heart Failure Trial**

<http://ClinicalTrials.gov/show/NCT00358215>

### **Study 14:**

**A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD**

<http://ClinicalTrials.gov/show/NCT01347710>

### **Study 15:**

**Ranolazine for Incomplete Vessel Revascularization Post-Percutaneous Coronary Intervention (PCI)**

<http://ClinicalTrials.gov/show/NCT01442038>

### **Study 16:**

**Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure**

<http://ClinicalTrials.gov/show/NCT01300013>

### **Study 17:**

**Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome**

<http://ClinicalTrials.gov/show/NCT00968708>

### **Study 18:**

**AngelMed for Early Recognition and Treatment of STEMI**

<http://ClinicalTrials.gov/show/NCT00781118>

### **Study 19:**

**Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)**

<http://ClinicalTrials.gov/show/NCT01147250>

### **Study 20:**

**Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy**

<http://ClinicalTrials.gov/show/NCT01121107>

### **Study 21:**

**Premium Migraine Trial**

<http://ClinicalTrials.gov/show/NCT00355056>

### **Study 22:**

**Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients—Efficacy and Safety: The CHI SQUARE Trial**

<http://ClinicalTrials.gov/show/NCT01201837>

### **Study 23:**

**A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation**

<http://ClinicalTrials.gov/show/NCT00910962>

### **Study 24:**

**Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI**

<http://ClinicalTrials.gov/show/NCT01313572>

### Study 25:

**Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy**

<http://ClinicalTrials.gov/show/NCT01076764>

### Study 26:

**Clinical Evaluation of Contact™ Therapy™ Cool Path™ Cardiac Ablation System in Conjunction With EnSite Velocity Contact™ Technology for the Treatment of Typical Atrial Flutter**

<http://ClinicalTrials.gov/show/NCT01401361>

### Study 27:

**Vest Prevention of Early Sudden Death Trial and VEST Registry**

<http://ClinicalTrials.gov/show/NCT01446965>

### Study 28:

**The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves**

<http://ClinicalTrials.gov/show/NCT01314313>

### Study 29:

**Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy**

<http://ClinicalTrials.gov/show/NCT01182441>

### Study 30:

**A Study to Evaluate the Effect of Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial Fibrillation (HARMONY)**

<http://ClinicalTrials.gov/show/NCT01522651>

### Study 31:

**Evaluate the Safety and Efficacy of OAS in Treating Severely Calcified Coronary Lesions**

<http://ClinicalTrials.gov/show/NCT01092416>

### Study 32:

**Evaluation of Exercise Treadmill Test Indices in Patients With Cardiovascular Disease**

<http://ClinicalTrials.gov/show/NCT01562041>

### Study 33:

**Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation**

<http://ClinicalTrials.gov/show/NCT00855712>

### Study 34:

**CANARY: Coronary Assessment by Near-infrared of Atherosclerotic Rupture-prone Yellow**

<http://ClinicalTrials.gov/show/NCT01268319>

### Study 35:

**Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure**

<http://ClinicalTrials.gov/show/NCT00803634>

### Study 36:

**A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure**

<http://ClinicalTrials.gov/show/NCT01357850>

### Study 37:

**Increase of Vagal Tone in CHF**

<http://ClinicalTrials.gov/show/NCT01303718>

### Study 38:

**A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention**

<http://ClinicalTrials.gov/show/NCT01327183>

### Study 39:

**Cardiox Shunt Detection Technology Study**

<http://ClinicalTrials.gov/show/NCT01333761>

### Study 40:

**Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin**

<http://ClinicalTrials.gov/show/NCT00958841>



### Study 41:

**Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)**

<http://ClinicalTrials.gov/show/NCT01327846>

### Study 42:

**Pivotal Clinical Study of the CardioFocus Endoscopic Ablation System—Adaptive Contact (EAS-AC) (HeartLight) in Patients With Paroxysmal Atrial Fibrillation (PAF)**

<http://ClinicalTrials.gov/show/NCT01456000>

### Study 43:

**Clinical Evaluation of Therapy™ Cool Flex™ Irrigated Ablation System for the Treatment of Typical Atrial Flutter**

<http://ClinicalTrials.gov/show/NCT01408485>

### Study 44:

**Insulin Resistance Intervention After Stroke Trial**

<http://ClinicalTrials.gov/show/NCT00091949>

### Study 45:

**The Cardiac Benefit of Testosterone Replacement in Men With Low Testosterone Levels With Coronary Artery Disease After Successful Intervention of the Blockage or Narrowed Heart Artery**

<http://ClinicalTrials.gov/show/NCT00413244>

### Study 46:

**The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure**

<http://ClinicalTrials.gov/show/NCT00944229>

### Study 47:

**Clarification of Optimal Anticoagulation Through Genetics**

<http://ClinicalTrials.gov/show/NCT00839657>

### Study 48:

**A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age**

<http://ClinicalTrials.gov/show/NCT01165580>

### Study 49:

**Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities**

<http://ClinicalTrials.gov/show/NCT01101035>

### Study 50:

**CINCOR™ Pivotal Trial**

<http://ClinicalTrials.gov/show/NCT01168024>

## Mental Illness

(111 clinical trials recruiting)

### Study 1:

**Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)**

<http://ClinicalTrials.gov/show/NCT01360866>

### Study 2:

**Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Polaris Trial)**

<http://ClinicalTrials.gov/show/NCT01360632>

### Study 3:

**Study of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder (the Pyxis Trial)**

<http://ClinicalTrials.gov/show/NCT01360645>

### Study 4:

**SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)**

<http://ClinicalTrials.gov/show/NCT01470469>

### Study 5:

**Efficacy in Prevention of Relapse of Schizophrenia in Subjects Taking Either Placebo or Iloperidone**

<http://ClinicalTrials.gov/show/NCT01291511>

### **Study 6:**

#### **A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease**

<http://ClinicalTrials.gov/show/NCT01485965>

### **Study 7:**

#### **Study of Arbaclofen for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders**

<http://ClinicalTrials.gov/show/NCT01288716>

### **Study 8:**

#### **Ecopipam Treatment of Tourette Syndrome**

<http://ClinicalTrials.gov/show/NCT01244633>

### **Study 9:**

#### **Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate**

<http://ClinicalTrials.gov/show/NCT01106430>

### **Study 10:**

#### **Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder**

<http://ClinicalTrials.gov/show/NCT01418339>

### **Study 11:**

#### **Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)**

<http://ClinicalTrials.gov/show/NCT01081145>

### **Study 12:**

#### **Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder**

<http://ClinicalTrials.gov/show/NCT01418352>

### **Study 13:**

#### **Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs**

<http://ClinicalTrials.gov/show/NCT01405053>

### **Study 14:**

#### **A Study to Evaluate the Efficacy and Safety of Molindone Hydrochloride XR Tablets as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)**

<http://ClinicalTrials.gov/show/NCT01364662>

### **Study 15:**

#### **A Study of RO5028442 in Adult Male High-Functioning Autistic Patients**

<http://ClinicalTrials.gov/show/NCT01474278>

### **Study 16:**

#### **A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis**

<http://ClinicalTrials.gov/show/NCT01174004>

### **Study 17:**

#### **A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis**

<http://ClinicalTrials.gov/show/NCT00550238>

### **Study 18:**

#### **A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features**

<http://ClinicalTrials.gov/show/NCT00637494>

### **Study 19:**

#### **Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features**

<http://ClinicalTrials.gov/show/NCT01122927>

### **Study 20:**

#### **Treatment of Sleep Problems in Children With Autism Spectrum Disorder With Melatonin**

<http://ClinicalTrials.gov/show/NCT00691080>

### **Study 21:**

#### **Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder**

<http://ClinicalTrials.gov/show/NCT01428661>

### **Study 22:**

#### **A Long-Term, Open-Label, Study on Schizophrenia**

<http://ClinicalTrials.gov/show/NCT01129674>

### **Study 23:**

#### **A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)**

<http://ClinicalTrials.gov/show/NCT01318434>

### **Study 24:**

#### **Safety, Tolerability, and Efficacy of Cariprazine for Patients With Bipolar Depression**

<http://ClinicalTrials.gov/show/NCT01396447>

### **Study 25:**

#### **Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder**

<http://ClinicalTrials.gov/show/NCT01469377>

### **Study 26:**

#### **Continued Safety Monitoring of Solanezumab in Alzheimer's Disease**

<http://ClinicalTrials.gov/show/NCT01127633>

### **Study 27:**

#### **Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole**

<http://ClinicalTrials.gov/show/NCT01432444>

### **Study 28:**

#### **Major Depressive Disorder With Mixed Features—Extension**

<http://ClinicalTrials.gov/show/NCT01423253>

### **Study 29:**

#### **Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression**

<http://ClinicalTrials.gov/show/NCT01361555>

### **Study 30:**

#### **PEARL Schizophrenia Maintenance**

<http://ClinicalTrials.gov/show/NCT01435928>

### **Study 31:**

#### **Major Depressive Disorder (MDD) With Mixed Features—Flexible Dose**

<http://ClinicalTrials.gov/show/NCT01421134>

### **Study 32:**

#### **Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder**

<http://ClinicalTrials.gov/show/NCT01121536>

### **Study 33:**

#### **SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder**

<http://ClinicalTrials.gov/show/NCT01435759>

### **Study 34:**

#### **A Long-Term Study in Schizophrenia**

<http://ClinicalTrials.gov/show/NCT01487083>

### **Study 35:**

#### **Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia**

<http://ClinicalTrials.gov/show/NCT01397786>

### **Study 36:**

#### **A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients**

<http://ClinicalTrials.gov/show/NCT01328093>

### **Study 37:**

#### **Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients**

<http://ClinicalTrials.gov/show/NCT00667810>

### **Study 38:**

**Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder**

<http://ClinicalTrials.gov/show/NCT01072630>

### **Study 39:**

**A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)**

<http://ClinicalTrials.gov/show/NCT01343966>

### **Study 40:**

**A Study in Prevention of Re-emergence of Depression Symptoms**

<http://ClinicalTrials.gov/show/NCT01299272>

### **Study 41:**

**ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment**

<http://ClinicalTrials.gov/show/NCT01457677>

### **Study 42:**

**Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression**

<http://ClinicalTrials.gov/show/NCT01369095>

### **Study 43:**

**A Study of LY2140023 in Patients With Schizophrenia**

<http://ClinicalTrials.gov/show/NCT01307800>

### **Study 44:**

**Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM2)**

<http://ClinicalTrials.gov/show/NCT01349907>

### **Study 45:**

**A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD**

<http://ClinicalTrials.gov/show/NCT01371708>

### **Study 46:**

**Efficacy and Safety of Asenapine Treatment for Pediatric Bipolar Disorder {P06107 Has an Extension (P05898; NCT01349907)}(P06107 AM2)**

<http://ClinicalTrials.gov/show/NCT01244815>

### **Study 47:**

**A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)**

<http://ClinicalTrials.gov/show/NCT01235520>

### **Study 48:**

**A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD**

<http://ClinicalTrials.gov/show/NCT01371734>

### **Study 49:**

**A Study in Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor**

<http://ClinicalTrials.gov/show/NCT01185340>

### **Study 50:**

**Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression**

<http://ClinicalTrials.gov/show/NCT01309945>

### **Study 51:**

**Efficacy and Safety Study of Low-Dose Ondansetron For Adjunctive Therapy In Adult Patients With Obsessive-Compulsive Disorder**

<http://ClinicalTrials.gov/show/NCT01275248>

### **Study 52:**

**Effect of Lu AA21004 Versus Escitalopram on Sexual Functioning in Adults With Well-Treated Major Depressive Disorder**

<http://ClinicalTrials.gov/show/NCT01364649>

### **Study 53:**

**Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder**

<http://ClinicalTrials.gov/show/NCT01436149>

#### **Study 54:**

**A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)**

<http://ClinicalTrials.gov/show/NCT01235559>

#### **Study 55:**

**A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25308)**

<http://ClinicalTrials.gov/show/NCT01192880>

#### **Study 56:**

**A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)**

<http://ClinicalTrials.gov/show/NCT01235585>

#### **Study 57:**

**Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder**

<http://ClinicalTrials.gov/show/NCT01467700>

#### **Study 58:**

**A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder**

<http://ClinicalTrials.gov/show/NCT01173601>

#### **Study 59:**

**Safety and Efficacy of F2695 SR in Adults With Fatigue Associated With Major Depressive Disorder**

<http://ClinicalTrials.gov/show/NCT01254305>

#### **Study 60:**

**A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)**

<http://ClinicalTrials.gov/show/NCT01192906>

#### **Study 61:**

**A Study in Pediatric Patients With Generalized Anxiety Disorder**

<http://ClinicalTrials.gov/show/NCT01226511>

#### **Study 62:**

**Efficacy Study of Lu AA21004 on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder**

<http://ClinicalTrials.gov/show/NCT01422213>

#### **Study 63:**

**Efficacy and Safety of Ramelteon Sublingual as Adjunctive Therapy for Maintenance Treatment of Bipolar I Disorder in Adult Patients**

<http://ClinicalTrials.gov/show/NCT01467713>

#### **Study 64:**

**Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor (SSRI)**

<http://ClinicalTrials.gov/show/NCT01361815>

#### **Study 65:**

**A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder**

<http://ClinicalTrials.gov/show/NCT01482221>

#### **Study 66:**

**Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia**

<http://ClinicalTrials.gov/show/NCT01488929>

#### **Study 67:**

**Major Depressive Disorder With Mixed Features**

<http://ClinicalTrials.gov/show/NCT01423240>

#### **Study 68:**

**A Study in Schizophrenia Patients**

<http://ClinicalTrials.gov/show/NCT01086748>

#### **Study 69:**

**Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients**

<http://ClinicalTrials.gov/show/NCT00723450>

### **Study 70:**

**Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder**

<http://ClinicalTrials.gov/show/NCT01436162>

### **Study 71:**

**A Study of RO4917838 in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310)**

<http://ClinicalTrials.gov/show/NCT01192867>

### **Study 72:**

**A Study of RO4917838 in Patients With Acute Exacerbation of Schizophrenia**

<http://ClinicalTrials.gov/show/NCT01234779>

### **Study 73:**

**Phase 3 IGIV, 10% in Alzheimer's Disease**

<http://ClinicalTrials.gov/show/NCT01524887>

### **Study 74:**

**Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease**

<http://ClinicalTrials.gov/show/NCT01561430>

### **Study 75:**

**Pharmacodynamic/Pharmacokinetic Study of AQW051 in Schizophrenia**

<http://ClinicalTrials.gov/show/NCT00825539>

### **Study 76:**

**A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease**

<http://ClinicalTrials.gov/show/NCT00960531>

### **Study 77:**

**VI-1121 for the Treatment Alzheimer's Disease**

<http://ClinicalTrials.gov/show/NCT01428362>

### **Study 78:**

**A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)**

<http://ClinicalTrials.gov/show/NCT01500200>

### **Study 79:**

**A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease**

<http://ClinicalTrials.gov/show/NCT01224106>

### **Study 80:**

**A Study of Flexible or Fixed Dose LLY2216684 as Adjunctive Treatment for Patients With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment**

<http://ClinicalTrials.gov/show/NCT01187407>

### **Study 81:**

**Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression**

<http://ClinicalTrials.gov/show/NCT01246908>

### **Study 82:**

**Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia**

<http://ClinicalTrials.gov/show/NCT01393613>

### **Study 83:**

**Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception**

<http://ClinicalTrials.gov/show/NCT01429116>

### **Study 84:**

**A Physical Dependence Study in Schizophrenia**

<http://ClinicalTrials.gov/show/NCT01452919>

### **Study 85:**

**Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome**

<http://ClinicalTrials.gov/show/NCT01498120>



### **Study 86:**

**Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia**

<http://ClinicalTrials.gov/show/NCT01396421>

### **Study 87:**

**Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)**

<http://ClinicalTrials.gov/show/NCT01312922>

### **Study 88:**

**Effect of Different Doses of SAR110894D on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil**

<http://ClinicalTrials.gov/show/NCT01266525>

### **Study 89:**

**A Study of the Effect of RO4917838 on Biomarker Measures of Cognitive Dysfunction in Patients With Schizophrenia**

<http://ClinicalTrials.gov/show/NCT01116830>

### **Study 90:**

**Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder**

<http://ClinicalTrials.gov/show/NCT01163032>

### **Study 91:**

**Synchronized Transcranial Magnetic Stimulation (sTMS) in Major Depressive Disorder**

<http://ClinicalTrials.gov/show/NCT01370733>

### **Study 92:**

**Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors**

<http://ClinicalTrials.gov/show/NCT01549834>

### **Study 93:**

**A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression**

<http://ClinicalTrials.gov/show/NCT01432236>

### **Study 94:**

**Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder**

<http://ClinicalTrials.gov/show/NCT01430754>

### **Study 95:**

**A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy**

<http://ClinicalTrials.gov/show/NCT01437657>

### **Study 96:**

**Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease**

<http://ClinicalTrials.gov/show/NCT00876863>

### **Study 97:**

**Lybrido for Female Sexual Dysfunction**

<http://ClinicalTrials.gov/show/NCT01432665>

### **Study 98:**

**Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients**

<http://ClinicalTrials.gov/show/NCT01489969>

### **Study 99:**

**Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults**

<http://ClinicalTrials.gov/show/NCT01266174>

### **Study 100:**

**Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease**

<http://ClinicalTrials.gov/show/NCT01492374>

### **Study 101:**

**Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome**

<http://ClinicalTrials.gov/show/NCT01495793>

### Study 102:

**A Safety, Tolerability and Pharmacokinetic Study of CPP-115**

<http://ClinicalTrials.gov/show/NCT01493596>

### Study 103:

**A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006**

<http://ClinicalTrials.gov/show/NCT01463098>

### Study 104:

**Cocaine Use Reduction With Buprenorphine**

<http://ClinicalTrials.gov/show/NCT01402492>

### Study 105:

**Multisite Controlled Trial of Cocaine Vaccine**

<http://ClinicalTrials.gov/show/NCT00969878>

### Study 106:

**Safety and Efficacy of Rasagiline in Restless Legs Syndrome**

<http://ClinicalTrials.gov/show/NCT01192503>

### Study 107:

**Pioglitazone for Heroin and for Nicotine Dependence**

<http://ClinicalTrials.gov/show/NCT01395797>

### Study 108:

**The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy**

<http://ClinicalTrials.gov/show/NCT00281502>

### Study 109:

**Nepicastat for Posttraumatic Stress Disorder (PTSD) in OIF/OEF Veterans**

<http://ClinicalTrials.gov/show/NCT00659230>

### Study 110:

**Zyprexa and Task Engagement in Schizophrenia**

<http://ClinicalTrials.gov/show/NCT00440843>

### Study 111:

**Effects of Pioglitazone, a PPARgamma Receptor Agonist, on the Abuse Liability of Oxycodone**

<http://ClinicalTrials.gov/show/NCT01395784>

## Stroke (16 clinical trials recruiting)

### Study 1:

**Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)**

<http://ClinicalTrials.gov/show/NCT00856661>

### Study 2:

**Carotid Stenting vs. Surgery of Severe Carotid Artery Disease and Stroke Prevention in Asymptomatic Patients (ACT I)**

<http://ClinicalTrials.gov/show/NCT00106938>

### Study 3:

**Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin**

<http://ClinicalTrials.gov/show/NCT01225562>

### Study 4:

**Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke**

<http://ClinicalTrials.gov/show/NCT01464307>

### Study 5:

**Dysport® Adult Lower Limb Spasticity Study**

<http://ClinicalTrials.gov/show/NCT01249404>

### Study 6:

**Evaluation of the WATCHMAN LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy**

<http://ClinicalTrials.gov/show/NCT01182441>

### **Study 7:**

#### **Insulin Resistance Intervention After Stroke Trial**

<http://ClinicalTrials.gov/show/NCT00091949>

### **Study 8:**

#### **Wake up Symptomatic Stroke—Benefit of Intravenous Clot Busters or Endovascular Intervention**

<http://ClinicalTrials.gov/show/NCT01455935>

### **Study 9:**

#### **Study of Botulinum Toxin and Recovery of Hand Function After Stroke**

<http://ClinicalTrials.gov/show/NCT01422161>

### **Study 10:**

#### **Clarification of Optimal Anticoagulation Through Genetics**

<http://ClinicalTrials.gov/show/NCT00839657>

### **Study 11:**

#### **Study of Idebenone in the Treatment of Mitochondrial Encephalopathy Lactic Acidosis & Stroke-like Episodes**

<http://ClinicalTrials.gov/show/NCT00887562>

### **Study 12:**

#### **Dysport® Adult Upper Limb Spasticity**

<http://ClinicalTrials.gov/show/NCT01313299>

### **Study 13:**

#### **Cardiovascular Outcomes Study of Alogliptin in Subjects With Type 2 Diabetes and Acute Coronary Syndrome**

<http://ClinicalTrials.gov/show/NCT00968708>

### **Study 14:**

#### **Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Comorbidities**

<http://ClinicalTrials.gov/show/NCT01101035>

### **Study 15:**

#### **Gadobutrol Enhanced MRA of the Supra-aortic Vessels**

<http://ClinicalTrials.gov/show/NCT01344447>

### **Study 16:**

#### **Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)**

<http://ClinicalTrials.gov/show/NCT01327846>



Pharmaceutical Research and Manufacturers of America  
950 F Street, NW, Washington, DC 20004

[www.phrma.org](http://www.phrma.org)